{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement.pdf",
  "annotations": [
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "CO-DEVELOPMENT AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "SFJ Pharmaceuticals X, Ltd.",
      "page_number": 0,
      "words": [
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "PB",
      "page_number": 0,
      "words": [
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "PhaseBio Pharmaceuticals Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "SFJ",
      "page_number": 0,
      "words": [
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "each, a \"Party\" and collectively, the \"Parties\").",
      "page_number": 0,
      "words": [
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "January 9, 2020",
      "page_number": 0,
      "words": [
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "January 9, 2020",
      "page_number": 0,
      "words": [
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Expiration Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement (the \"Term\") will commence on the Effective Date and will expire upon the earliest of (i) termination of this Agreement in accordance with Section 14.2, or (ii) the date of payment of the last Approval Payment due based on all applicable Regulatory Approvals which have been received.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement (the \"Term\") will commence on the Effective Date and will expire upon the earliest of (i) termination of this Agreement in accordance with Section 14.2, or (ii) the date of payment of the last Approval Payment due based on all applicable Regulatory Approvals which have been received.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Governing Law_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "The construction and validity of this Agreement and the provisions hereof, and the rights and obligations of the Parties hereunder, will be governed by the internal laws of the State of Delaware, USA, and, to the extent applicable to Patents and Trademarks, the applicable federal laws of the USA, in each instance without regard to conflict of laws principles.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Governing Law_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "The construction and validity of this Agreement and the provisions hereof, and the rights and obligations of the Parties hereunder, will be governed by the internal laws of the State of Delaware, USA, and, to the extent applicable to Patents and Trademarks, the applicable federal laws of the USA, in each instance without regard to conflict of laws principles.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Non-Compete_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector? ",
      "answer_text": "During the applicable Exclusive Period, SFJ shall not, and shall cause its Affiliates not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold:\n\n3.19.1 any Competing Product (other than Product) alone or in combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients;\n\n3.19.2 any combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients of the Product and a Competing Product;\n\n3.19.3 any agent that is intended as an antidote to, or is intended to neutralize, abrogate or reverse the antiplatelet activity of, (i) any Brilinta Competing Product alone or in combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients or (ii) both the Ticagrelor Compound and a Brilinta Competing Product;\n\n3.19.4 without limitation to the foregoing, any agent with dual activity as (i) an antidote to, or for use as an agent to neutralize, abrogate or reverse the antiplatelet activity of, the Ticagrelor Compound and (ii) an antidote to, or for use as an agent to neutralize, abrogate or reverse the antiplatelet activity of, any Brilinta Competing Product; or\n\n3.19.5 any Brilinta Competing Product.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector? ",
      "answer_text": "During the applicable Exclusive Period, SFJ shall not, and shall cause its Affiliates not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold:\n\n3.19.1 any Competing Product (other than Product) alone or in combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients;\n\n3.19.2 any combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients of the Product and a Competing Product;\n\n3.19.3 any agent that is intended as an antidote to, or is intended to neutralize, abrogate or reverse the antiplatelet activity of, (i) any Brilinta Competing Product alone or in combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients or (ii) both the Ticagrelor Compound and a Brilinta Competing Product;\n\n3.19.4 without limitation to the foregoing, any agent with dual activity as (i) an antidote to, or for use as an agent to neutralize, abrogate or reverse the antiplatelet activity of, the Ticagrelor Compound and (ii) an antidote to, or for use as an agent to neutralize, abrogate or reverse the antiplatelet activity of, any Brilinta Competing Product; or\n\n3.19.5 any Brilinta Competing Product.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Exclusivity_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "SFJ shall use commercially reasonable efforts to obtain from each Third Party contractor that SFJ or its Affiliate proposes to engage to conduct activities under or in connection with this Agreement on behalf of SFJ or its Affiliates (i) an assignment, (ii) an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, or (iii) a non‑exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers ((i) through (iii) in order of preference), to PB of any Trial Invention that such Third Party contractor conceives, discovers, develops or otherwise makes in connection with activities conducted relating to this Agreement.",
      "page_number": 3,
      "words": [
        {
          "text": "immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at",
          "bbox": [
            283.0,
            345.0,
            2992.0,
            389.0
          ],
          "confidence": 0.9966195821762085
        },
        {
          "text": "least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of",
          "bbox": [
            281.0,
            413.0,
            2972.0,
            457.0
          ],
          "confidence": 0.9941709041595459
        },
        {
          "text": "the surviving entity immediately after such merger, reorganization or consolidation, (b) a transaction in which a Third Party becomes",
          "bbox": [
            279.0,
            477.0,
            3027.0,
            526.0
          ],
          "confidence": 0.9948112964630127
        },
        {
          "text": "the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of PB, other than",
          "bbox": [
            281.0,
            545.0,
            2962.0,
            588.0
          ],
          "confidence": 0.9884380102157593
        },
        {
          "text": "through the issuance of voting securities for the purpose of raising financing to one or more financial or institutional investors that",
          "bbox": [
            277.0,
            607.0,
            2951.0,
            658.0
          ],
          "confidence": 0.9930377006530762
        },
        {
          "text": "are not then controlled by an entity engaged in the development or commercialization of pharmaceutical or biotechnology products.",
          "bbox": [
            281.0,
            680.0,
            3016.0,
            724.0
          ],
          "confidence": 0.9945303797721863
        },
        {
          "text": "or (c) the sale or other transfer of all or substantially all of PB's business or assets relating to the Product for use in the Indication.",
          "bbox": [
            281.0,
            742.0,
            2978.0,
            789.0
          ],
          "confidence": 0.9938036203384399
        },
        {
          "text": "A Licensing Transaction shall not constitute a Change of Control, unless such Licensing Transaction includes the grant of US",
          "bbox": [
            283.0,
            811.0,
            2869.0,
            855.0
          ],
          "confidence": 0.9938583374023438
        },
        {
          "text": "Commercialization Rights in which event such Licensing Transaction shall be deemed to be a Change in Control.",
          "bbox": [
            279.0,
            875.0,
            2626.0,
            925.0
          ],
          "confidence": 0.9910343885421753
        },
        {
          "text": "1.1.26 \"Change of Control Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.2",
          "bbox": [
            618.0,
            998.0,
            2762.0,
            1042.0
          ],
          "confidence": 0.9888197779655457
        },
        {
          "text": "1.1.27 \"Claim\"' means any Third Party claim, demand, suit and/or cause of action..",
          "bbox": [
            614.0,
            1122.0,
            2322.0,
            1171.0
          ],
          "confidence": 0.973606288433075
        },
        {
          "text": "1.1.28 \"Clinical Investigator' means the principal investigator at each Site..",
          "bbox": [
            618.0,
            1250.0,
            2157.0,
            1299.0
          ],
          "confidence": 0.9836348295211792
        },
        {
          "text": "1.1.29 \"Clinical Investigator Meeting\"' has the meaning ascribed to such term in Section 3.2.2.1.",
          "bbox": [
            613.0,
            1370.0,
            2623.0,
            1427.0
          ],
          "confidence": 0.9799399375915527
        },
        {
          "text": "1.1.30 \"Clinical Supply Agreement\" has the meaning ascribed to such term in Section 3.14.1.2..",
          "bbox": [
            618.0,
            1504.0,
            2608.0,
            1548.0
          ],
          "confidence": 0.9876052141189575
        },
        {
          "text": "1.1.31 \"Clinical Supply Agreement' has the meaning ascribed to such term in Section 3.14.1.1..",
          "bbox": [
            616.0,
            1628.0,
            2614.0,
            1678.0
          ],
          "confidence": 0.989601731300354
        },
        {
          "text": "1.1.32 \"Clinical Trials\"' means the Phase 3 Trial, any required supplemental clinical trial of the Product in China",
          "bbox": [
            616.0,
            1756.0,
            2922.0,
            1805.0
          ],
          "confidence": 0.9894689321517944
        },
        {
          "text": "contemplated by the Development Plan, and the pharmacokinetic study of the Product in Japanese Subjects contemplated by the",
          "bbox": [
            283.0,
            1829.0,
            2980.0,
            1873.0
          ],
          "confidence": 0.992023229598999
        },
        {
          "text": "Development Plan.",
          "bbox": [
            281.0,
            1895.0,
            676.0,
            1939.0
          ],
          "confidence": 0.9894911646842957
        },
        {
          "text": "1.1.33 \"Clinical Trial Activity\"' has the meaning ascribed to such term in Section 2.3.1.",
          "bbox": [
            616.0,
            2014.0,
            2414.0,
            2063.0
          ],
          "confidence": 0.9907666444778442
        },
        {
          "text": "1.1.34 \"Clinical Trial Agreement' has the meaning ascribed to such term in Section 3.2.1.3..",
          "bbox": [
            618.0,
            2140.0,
            2527.0,
            2189.0
          ],
          "confidence": 0.9826359748840332
        },
        {
          "text": "1.1.35 \"Clinical Trials Database\"' has the meaning ascribed to such term in Section 3.5.3.1..",
          "bbox": [
            616.0,
            2264.0,
            2518.0,
            2315.0
          ],
          "confidence": 0.9898077845573425
        },
        {
          "text": "1.1.36 \"Clinical Trials Master File' has the meaning ascribed to such term in Section 3.5.4..",
          "bbox": [
            614.0,
            2390.0,
            2514.0,
            2441.0
          ],
          "confidence": 0.9892297387123108
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9978482723236084
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Exclusivity_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "SFJ shall use commercially reasonable efforts to obtain from each Third Party contractor that SFJ or its Affiliate proposes to engage to conduct activities under or in connection with this Agreement on behalf of SFJ or its Affiliates (i) an assignment, (ii) an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, or (iii) a non‑exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers ((i) through (iii) in order of preference), to PB of any Trial Invention that such Third Party contractor conceives, discovers, develops or otherwise makes in connection with activities conducted relating to this Agreement.",
      "page_number": 4,
      "words": [
        {
          "text": "1.1.37 \"CMC\" means chemistry, manufacturing and controls.",
          "bbox": [
            616.0,
            336.0,
            1892.0,
            387.0
          ],
          "confidence": 0.9906229972839355
        },
        {
          "text": "1.1.38 \"CMC Information\" means the CMC information intended or required for the submission of an IND or",
          "bbox": [
            616.0,
            464.0,
            2929.0,
            510.0
          ],
          "confidence": 0.9926297664642334
        },
        {
          "text": "BLA.",
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ],
          "confidence": 0.9989228248596191
        },
        {
          "text": "1.1.39 \"CMO\" means contract manufacturing organization or contract development and manufacturing",
          "bbox": [
            614.0,
            654.0,
            2768.0,
            709.0
          ],
          "confidence": 0.9910363554954529
        },
        {
          "text": "organization.",
          "bbox": [
            277.0,
            723.0,
            540.0,
            781.0
          ],
          "confidence": 0.9975845813751221
        },
        {
          "text": "1.1.40 \"Commercial Launch' means, with respect to the Product and a country in the Territory, the first sale to a.",
          "bbox": [
            616.0,
            848.0,
            2971.0,
            899.0
          ],
          "confidence": 0.9816547632217407
        },
        {
          "text": "Third Party of such Product in such country after (a) Regulatory Approval and (b) in any country in which price approval is",
          "bbox": [
            281.0,
            925.0,
            2855.0,
            968.0
          ],
          "confidence": 0.984332263469696
        },
        {
          "text": "necessary or relevant for a majority of the population to obtain access to pharmaceutical products, price approval for such Product",
          "bbox": [
            275.0,
            987.0,
            3029.0,
            1038.0
          ],
          "confidence": 0.9829985499382019
        },
        {
          "text": "in such country.",
          "bbox": [
            277.0,
            1052.0,
            602.0,
            1106.0
          ],
          "confidence": 0.9959282875061035
        },
        {
          "text": "1.1.41 \"Commercialization'' or \"Commercialize\" means the commercial manufacture, marketing, promotion, sale",
          "bbox": [
            614.0,
            1175.0,
            2962.0,
            1228.0
          ],
          "confidence": 0.9898544549942017
        },
        {
          "text": "and/or distribution of the Product. For clarity, Commercialization excludes all activities associated with development and seeking",
          "bbox": [
            281.0,
            1246.0,
            2962.0,
            1294.0
          ],
          "confidence": 0.9963714480400085
        },
        {
          "text": "Regulatory Approval for the Product..",
          "bbox": [
            279.0,
            1312.0,
            1062.0,
            1363.0
          ],
          "confidence": 0.9807345271110535
        },
        {
          "text": "1.1.42 \"Commercially Reasonable Efforts\"' means with respect to the performance of activities under this",
          "bbox": [
            614.0,
            1436.0,
            2809.0,
            1486.0
          ],
          "confidence": 0.9854094982147217
        },
        {
          "text": "Agreement by a Party (as pertains to its role in conducting the Clinical Trials): reasonable, diligent, good-faith efforts to accomplish",
          "bbox": [
            277.0,
            1504.0,
            3011.0,
            1557.0
          ],
          "confidence": 0.9930388331413269
        },
        {
          "text": "such objective which are consistent with industry standards for companies of comparable size as that of such Party. \"Commercially",
          "bbox": [
            281.0,
            1577.0,
            3009.0,
            1621.0
          ],
          "confidence": 0.9955451488494873
        },
        {
          "text": "Reasonable Efforts' requires, with respect to a particular task or activity in making, using, selling, offering for sale, importing,",
          "bbox": [
            277.0,
            1639.0,
            2884.0,
            1692.0
          ],
          "confidence": 0.9913605451583862
        },
        {
          "text": "exporting, developing (including seeking regulatory approvals or applicable pricing or reimbursement approvals) or otherwise.",
          "bbox": [
            279.0,
            1705.0,
            2898.0,
            1758.0
          ],
          "confidence": 0.995408296585083
        },
        {
          "text": "commercializing the Product, that a Party: (i) promptly assign responsibility for such task or activity to specific employee(s) who.",
          "bbox": [
            279.0,
            1774.0,
            2953.0,
            1824.0
          ],
          "confidence": 0.9884916543960571
        },
        {
          "text": "are held accountable for progress and monitor such progress on an on-going basis; (ii) set and consistently seek to achieve specific",
          "bbox": [
            279.0,
            1840.0,
            3016.0,
            1889.0
          ],
          "confidence": 0.9896214604377747
        },
        {
          "text": "and meaningful objectives for carrying out such task or activity; and (iii) make and implement decisions and allocate resources.",
          "bbox": [
            281.0,
            1906.0,
            2911.0,
            1955.0
          ],
          "confidence": 0.994252622127533
        },
        {
          "text": "designed to advance progress with respect to such objectives in accordance with established timelines; provided, however, that, to",
          "bbox": [
            279.0,
            1972.0,
            3016.0,
            2023.0
          ],
          "confidence": 0.9976450800895691
        },
        {
          "text": "the extent that the performance of a Party's obligations hereunder is adversely affected by the other Party's breach in performing its",
          "bbox": [
            281.0,
            2043.0,
            3021.0,
            2087.0
          ],
          "confidence": 0.9909575581550598
        },
        {
          "text": "obligations hereunder, the impact on the first Party of such performance failure by the other Party will be taken into account in.",
          "bbox": [
            279.0,
            2105.0,
            2909.0,
            2156.0
          ],
          "confidence": 0.9834312796592712
        },
        {
          "text": "determining whether the first Party has used its Commercially Reasonable Efforts to perform any such affected obligations.",
          "bbox": [
            283.0,
            2176.0,
            2833.0,
            2220.0
          ],
          "confidence": 0.9969245195388794
        },
        {
          "text": "1.1.43 \"Competing Product\" means any agent intended to neutralize, abrogate or reverse the antiplatelet activity of",
          "bbox": [
            618.0,
            2299.0,
            3020.0,
            2343.0
          ],
          "confidence": 0.9894914627075195
        },
        {
          "text": "the Ticagrelor Compound.",
          "bbox": [
            279.0,
            2366.0,
            828.0,
            2416.0
          ],
          "confidence": 0.9743116497993469
        },
        {
          "text": "1.1.44 \"Completion Date\"' means, as to a particular Clinical Trial, the earlier of (a) the date of final database lock.",
          "bbox": [
            614.0,
            2489.0,
            2976.0,
            2538.0
          ],
          "confidence": 0.9890645742416382
        },
        {
          "text": "for such Clinical Trial and (b) the date such Clinical Trial or this Agreement is terminated.",
          "bbox": [
            281.0,
            2560.0,
            2132.0,
            2604.0
          ],
          "confidence": 0.9939261674880981
        },
        {
          "text": "1.1.45 \"Confidential Information\" of a Party means all information and materials provided and/or disclosed",
          "bbox": [
            618.0,
            2683.0,
            2847.0,
            2726.0
          ],
          "confidence": 0.9938953518867493
        },
        {
          "text": "(including in written form, electronic form or otherwise) by,",
          "bbox": [
            277.0,
            2748.0,
            1512.0,
            2805.0
          ],
          "confidence": 0.9992232918739319
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9815122485160828
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BLA.",
          "page": 4,
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Competitive Restriction Exception_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
      "answer_text": "Notwithstanding any of the foregoing, without the consent of PB, which consent may be withheld in PB's sole discretion, SFJ shall not sell, assign, sublicense or otherwise transfer this Agreement to an entity whose primary business is the development or commercialization of pharmaceutical or biotechnology products prior to the date of Program Transfer. For the avoidance of doubt the preceding sentence shall not apply after the date of Program Transfer.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Competitive Restriction Exception_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
      "answer_text": "Notwithstanding any of the foregoing, without the consent of PB, which consent may be withheld in PB's sole discretion, SFJ shall not sell, assign, sublicense or otherwise transfer this Agreement to an entity whose primary business is the development or commercialization of pharmaceutical or biotechnology products prior to the date of Program Transfer. For the avoidance of doubt the preceding sentence shall not apply after the date of Program Transfer.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__No-Solicit Of Employees_53_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party’s soliciting or hiring employees and/or contractors from the  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "Notwithstanding the foregoing, nothing herein shall restrict or preclude the Parties' right to make generalized searches for employees by way of a general solicitation for employment placed in a trade journal, newspaper or website.",
      "page_number": 53,
      "words": [
        {
          "text": "replacement of the SVB Loan Agreement, enter into a new subordination agreement with a new lender(s) on terms and conditions",
          "bbox": [
            281.0,
            344.0,
            3003.0,
            387.0
          ],
          "confidence": 0.9995290040969849
        },
        {
          "text": "that are taken as a whole not less favorable in any material respect to SFJ than those set forth in the subordination agreement to be",
          "bbox": [
            281.0,
            411.0,
            3011.0,
            455.0
          ],
          "confidence": 0.9939222931861877
        },
        {
          "text": "entered into with SVB, and (d) otherwise be in form and substance reasonably satisfactory to SFJ. Upon the execution of such.",
          "bbox": [
            283.0,
            479.0,
            2936.0,
            523.0
          ],
          "confidence": 0.9922934770584106
        },
        {
          "text": "new subordination agreement with such new lender(s), references herein to \"SVB'' shall refer to such new lender(s), references",
          "bbox": [
            281.0,
            545.0,
            2938.0,
            588.0
          ],
          "confidence": 0.9916369915008545
        },
        {
          "text": "herein to the \"SVB Loan'' shall refer to the loans provided by such new lender (provided that the aggregate principal amount of",
          "bbox": [
            275.0,
            607.0,
            2951.0,
            660.0
          ],
          "confidence": 0.9973737001419067
        },
        {
          "text": "such loans shall not exceed [***D), references herein to the \"SVB Collateral' shall refer to the collateral securing such new loan,",
          "bbox": [
            279.0,
            676.0,
            2962.0,
            725.0
          ],
          "confidence": 0.9819372296333313
        },
        {
          "text": "and references herein to the \"SVB Loan Agreement' shall refer to such loan and security agreement or similar document entered",
          "bbox": [
            279.0,
            740.0,
            2973.0,
            791.0
          ],
          "confidence": 0.9842204451560974
        },
        {
          "text": "into with such new lender(s)..",
          "bbox": [
            279.0,
            808.0,
            874.0,
            855.0
          ],
          "confidence": 0.9782766699790955
        },
        {
          "text": "7.5 Negative Covenants.",
          "bbox": [
            448.0,
            928.0,
            963.0,
            978.0
          ],
          "confidence": 0.9985463619232178
        },
        {
          "text": "7.5.1 Incurrence of Certain Indebtedness. PB shall not, without SFJ's prior written consent, create, incur, assume,.",
          "bbox": [
            613.0,
            1054.0,
            3005.0,
            1109.0
          ],
          "confidence": 0.9908298254013062
        },
        {
          "text": "or be liable for any Indebtedness, or permit any subsidiary of PB to do so, other than Permitted Indebtedness..",
          "bbox": [
            281.0,
            1127.0,
            2585.0,
            1177.0
          ],
          "confidence": 0.9912606477737427
        },
        {
          "text": "7.5.2 Subordinated Debt. PB shall not (a) make or permit any payment on any Subordinated Debt, except to the",
          "bbox": [
            613.0,
            1246.0,
            2985.0,
            1303.0
          ],
          "confidence": 0.9934866428375244
        },
        {
          "text": "extent permitted by the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is",
          "bbox": [
            279.0,
            1317.0,
            2944.0,
            1371.0
          ],
          "confidence": 0.9968878626823425
        },
        {
          "text": "subject, or (b) amend any provision in any document relating to Subordinated Debt which would provide for earlier or greater",
          "bbox": [
            283.0,
            1391.0,
            2918.0,
            1434.0
          ],
          "confidence": 0.9900172352790833
        },
        {
          "text": "principal, interest, or other cash payments thereon, or materially adversely affect the subordination thereof to PB Obligations owed",
          "bbox": [
            277.0,
            1451.0,
            3016.0,
            1506.0
          ],
          "confidence": 0.9931237101554871
        },
        {
          "text": "to SFJ.",
          "bbox": [
            269.0,
            1514.0,
            434.0,
            1574.0
          ],
          "confidence": 0.9853449463844299
        },
        {
          "text": "7.5.3 Encumbrances. PB shall not, without SFJ's prior written consent:",
          "bbox": [
            614.0,
            1641.0,
            2101.0,
            1692.0
          ],
          "confidence": 0.9925510883331299
        },
        {
          "text": "7.5.3.1 create, incur, allow, or suffer any Lien on any of the PB Intellectual Property, or assign or convey",
          "bbox": [
            783.0,
            1765.0,
            2976.0,
            1822.0
          ],
          "confidence": 0.9903187155723572
        },
        {
          "text": "any right to receive income with respect to the PB Intellectual Property (other than royalty and other license fee obligations to",
          "bbox": [
            281.0,
            1840.0,
            2907.0,
            1889.0
          ],
          "confidence": 0.9965915083885193
        },
        {
          "text": "licensors thereof in accordance with the applicable license agreement), including the sale of any PB Intellectual Property, or permit",
          "bbox": [
            279.0,
            1908.0,
            3003.0,
            1957.0
          ],
          "confidence": 0.996095597743988
        },
        {
          "text": "any of its subsidiaries to do so, other than Liens in favor of SVB (subject in all respects to the terms and conditions of the.",
          "bbox": [
            281.0,
            1974.0,
            2820.0,
            2017.0
          ],
          "confidence": 0.9919012784957886
        },
        {
          "text": "subordination agreement contemplated by Section 7.4 hereof) and other Permitted Liens that are permitted pursuant to the terms",
          "bbox": [
            281.0,
            2043.0,
            2976.0,
            2087.0
          ],
          "confidence": 0.9981175065040588
        },
        {
          "text": "of this Agreement; or.",
          "bbox": [
            279.0,
            2105.0,
            727.0,
            2160.0
          ],
          "confidence": 0.9746027588844299
        },
        {
          "text": "7.5.3.2 except as and to the extent permitted by Section 7.5.6, enter into any agreement, document,",
          "bbox": [
            783.0,
            2228.0,
            2882.0,
            2281.0
          ],
          "confidence": 0.9777225255966187
        },
        {
          "text": "instrument or other arrangement (except with or in favor of SFJ or SVB) with any Person which directly or indirectly prohibits or",
          "bbox": [
            277.0,
            2301.0,
            2980.0,
            2350.0
          ],
          "confidence": 0.9925428032875061
        },
        {
          "text": "has the effect of prohibiting PB or any subsidiary of PB from assigning, mortgaging, pledging, granting a security interest in or upon.",
          "bbox": [
            274.0,
            2361.0,
            3011.0,
            2423.0
          ],
          "confidence": 0.9857593774795532
        },
        {
          "text": "or encumbering any proceeds from PB Intellectual Property..",
          "bbox": [
            277.0,
            2430.0,
            1542.0,
            2485.0
          ],
          "confidence": 0.9899924993515015
        },
        {
          "text": "7.5.4 Distributions; Investments. PB shall not, without SFJ's prior written consent, (a) pay any dividends or make.",
          "bbox": [
            613.0,
            2553.0,
            2992.0,
            2606.0
          ],
          "confidence": 0.9896194934844971
        },
        {
          "text": "any distribution or payment on account of or redeem, retire or purchase any capital stock, provided that (i) PB may convert any of.",
          "bbox": [
            279.0,
            2624.0,
            3021.0,
            2675.0
          ],
          "confidence": 0.989717423915863
        },
        {
          "text": "its equity convertible securities into other equity securities (or cash for partial shares) pursuant to the terms of such equity",
          "bbox": [
            275.0,
            2688.0,
            2804.0,
            2747.0
          ],
          "confidence": 0.9929426908493042
        },
        {
          "text": "convertible securities or otherwise in exchange thereof, (ii) PB may pay dividends",
          "bbox": [
            281.0,
            2759.0,
            1986.0,
            2809.0
          ],
          "confidence": 0.9995732307434082
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9866588711738586
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__No-Solicit Of Employees_54_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party’s soliciting or hiring employees and/or contractors from the  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "Notwithstanding the foregoing, nothing herein shall restrict or preclude the Parties' right to make generalized searches for employees by way of a general solicitation for employment placed in a trade journal, newspaper or website.",
      "page_number": 54,
      "words": [
        {
          "text": "solely in common stock, and (iii) PB may repurchase the stock of former employees or consultants pursuant to stock repurchase",
          "bbox": [
            281.0,
            345.0,
            2965.0,
            389.0
          ],
          "confidence": 0.9907211661338806
        },
        {
          "text": "agreements, provided that the aggregate amount of all such repurchases does not exceed [***] Dollars ($[***]) per fiscal year, or",
          "bbox": [
            276.0,
            404.0,
            3020.0,
            464.0
          ],
          "confidence": 0.991024374961853
        },
        {
          "text": "(b) directly or indirectly make any Prohibited Investment (including, without limitation, by the formation of or through any",
          "bbox": [
            279.0,
            477.0,
            2806.0,
            528.0
          ],
          "confidence": 0.9927078485488892
        },
        {
          "text": "subsidiary), or permit any of its subsidiaries to do so. For the avoidance of doubt, nothing in this Section 7.5.4 shall limit the ability",
          "bbox": [
            281.0,
            543.0,
            3000.0,
            592.0
          ],
          "confidence": 0.9885690808296204
        },
        {
          "text": "of PB to pay or settle on conversion (in cash or equity) any convertible indebtedness.",
          "bbox": [
            281.0,
            612.0,
            2061.0,
            656.0
          ],
          "confidence": 0.9973058700561523
        },
        {
          "text": "7.5.5 Licensing Transactions. PB shall have the right, without SFJ's consent, to enter into any Excluded Licensing",
          "bbox": [
            614.0,
            725.0,
            2987.0,
            786.0
          ],
          "confidence": 0.9927489757537842
        },
        {
          "text": "Transaction. PB shall not, without SFJ's prior written consent, enter into a Licensing Transaction unless such Licensing Transaction",
          "bbox": [
            277.0,
            802.0,
            3007.0,
            848.0
          ],
          "confidence": 0.987877607345581
        },
        {
          "text": "is an Excluded Licensing Transaction (in which case such prohibition shall not apply and no such consent of SFJ shall be required);.",
          "bbox": [
            274.0,
            862.0,
            3011.0,
            921.0
          ],
          "confidence": 0.9906054139137268
        },
        {
          "text": "provided that SFJ shall only be entitled to withhold such consent as to a Licensing Transaction other than an Excluded Licensing",
          "bbox": [
            274.0,
            928.0,
            2960.0,
            992.0
          ],
          "confidence": 0.9983089566230774
        },
        {
          "text": "Transaction in the event SFJ reasonably determines, and provides PB with written notice of its determination within [***] of PB",
          "bbox": [
            277.0,
            998.0,
            2954.0,
            1051.0
          ],
          "confidence": 0.9903832077980042
        },
        {
          "text": "providing to SFJ a non-binding term sheet or comparable document summarizing the material terms of the proposed Licensing",
          "bbox": [
            277.0,
            1069.0,
            2920.0,
            1120.0
          ],
          "confidence": 0.9918771386146545
        },
        {
          "text": "Transaction [***], that PB entering into such Licensing Transaction would [***] (\"Material Impact'). If PB disagrees with SFJ's",
          "bbox": [
            279.0,
            1133.0,
            2974.0,
            1182.0
          ],
          "confidence": 0.9785155057907104
        },
        {
          "text": "determination, the matter shall be submitted to arbitration before a single neutral arbitrator under the American Arbitration.",
          "bbox": [
            281.0,
            1204.0,
            2828.0,
            1248.0
          ],
          "confidence": 0.9865661263465881
        },
        {
          "text": "Association's (AAA's) expedited arbitration rules, which arbitrator shall be mutually agreeable to both Parties and have significant",
          "bbox": [
            283.0,
            1272.0,
            2991.0,
            1316.0
          ],
          "confidence": 0.9960454106330872
        },
        {
          "text": "expertise on the subject matter to be decided (provided that if the Parties have not mutually agreed on such arbitrator within J***]",
          "bbox": [
            279.0,
            1334.0,
            3003.0,
            1385.0
          ],
          "confidence": 0.9911063313484192
        },
        {
          "text": "arbitrator's award to be rendered within [***] of the applicable demand for arbitration. The sole issue to be decided in the",
          "bbox": [
            277.0,
            1464.0,
            2857.0,
            1520.0
          ],
          "confidence": 0.9937563538551331
        },
        {
          "text": "arbitration shall be whether the entry into such Licensing Transaction by PB would have a substantial likelihood of having a",
          "bbox": [
            281.0,
            1535.0,
            2842.0,
            1584.0
          ],
          "confidence": 0.9949465394020081
        },
        {
          "text": "Material Impact. In the event the arbitrator agrees with SFJ, PB shall not be entitled to enter into such Licensing Transaction. In the.",
          "bbox": [
            275.0,
            1599.0,
            3025.0,
            1650.0
          ],
          "confidence": 0.9912943243980408
        },
        {
          "text": "event the arbitrator agrees with PB, PB shall be entitled to enter into the Licensing Transaction; [***], and, [***].",
          "bbox": [
            276.0,
            1663.0,
            2663.0,
            1723.0
          ],
          "confidence": 0.987165093421936
        },
        {
          "text": "7.5.6 Sales of Royalty Streams. PB shall not sell, transfer or assign, directly or indirectly, in whole or in part, any",
          "bbox": [
            613.0,
            1785.0,
            2965.0,
            1844.0
          ],
          "confidence": 0.9877910614013672
        },
        {
          "text": "rights to receive payments of royalties or license fees with respect to the Product or the PB Intellectual Property (including any.",
          "bbox": [
            275.0,
            1858.0,
            2925.0,
            1915.0
          ],
          "confidence": 0.9946429133415222
        },
        {
          "text": "Accounts with respect to such royalties or license fees), other than to a wholly owned direct or indirect subsidiary of PB (it being",
          "bbox": [
            274.0,
            1919.0,
            2982.0,
            1986.0
          ],
          "confidence": 0.992828369140625
        },
        {
          "text": "understood that the foregoing shall not restrict the creation of any Permitted Lien).",
          "bbox": [
            281.0,
            1997.0,
            1992.0,
            2041.0
          ],
          "confidence": 0.9953686594963074
        },
        {
          "text": "7.5.7 Further Negative Pledges. PB shall not, from and after the Effective Date, enter into any agreement that",
          "bbox": [
            613.0,
            2114.0,
            2905.0,
            2167.0
          ],
          "confidence": 0.994815468788147
        },
        {
          "text": "prohibits or limits the ability of PB to create, incur, assume or suffer to exist any Lien upon any PB Intellectual Property (including",
          "bbox": [
            279.0,
            2187.0,
            2983.0,
            2239.0
          ],
          "confidence": 0.9867552518844604
        },
        {
          "text": "any Accounts with respect to such royalties or license fees), whether now owned or hereafter acquired, to secure the PB.",
          "bbox": [
            277.0,
            2251.0,
            2815.0,
            2304.0
          ],
          "confidence": 0.993133008480072
        },
        {
          "text": "Obligations, other than (a) agreements with SFJ (including this Agreement), (b) any agreements governing purchase money Liens",
          "bbox": [
            277.0,
            2319.0,
            2973.0,
            2372.0
          ],
          "confidence": 0.9937551021575928
        },
        {
          "text": "or capital lease obligations otherwise permitted hereby (in which case, any such prohibition or limitation shall only be effective on",
          "bbox": [
            281.0,
            2390.0,
            2969.0,
            2434.0
          ],
          "confidence": 0.998075544834137
        },
        {
          "text": "the assets financed thereby), (c) customary restrictions on assignment contained in leases, licenses or other",
          "bbox": [
            279.0,
            2454.0,
            2510.0,
            2503.0
          ],
          "confidence": 0.9929087162017822
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9840149283409119
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__No-Solicit Of Employees_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party’s soliciting or hiring employees and/or contractors from the  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "During the Term and for a period of [***] thereafter, neither Party shall solicit an employee of the other Party who is or has been involved in the performance or oversight of any of the development activities hereunder to terminate his or her employment and accept employment or work as a consultant with the soliciting Party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__No-Solicit Of Employees_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party’s soliciting or hiring employees and/or contractors from the  counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "During the Term and for a period of [***] thereafter, neither Party shall solicit an employee of the other Party who is or has been involved in the performance or oversight of any of the development activities hereunder to terminate his or her employment and accept employment or work as a consultant with the soliciting Party.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "PB shall not, without SFJ's prior written consent, enter into a Licensing Transaction unless such Licensing Transaction is an Excluded Licensing Transaction (in which case such prohibition shall not apply and no such consent of SFJ shall be required); provided that SFJ shall only be entitled to withhold such consent as to a Licensing Transaction other than an Excluded Licensing Transaction in the event SFJ reasonably determines, and provides PB with written notice of its determination within [***] of PB providing to SFJ a non-binding term sheet or comparable document summarizing the material terms of the proposed Licensing Transaction [***], that PB entering into such Licensing Transaction would [***] (\"Material Impact\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "PB shall not, without SFJ's prior written consent, enter into a Licensing Transaction unless such Licensing Transaction is an Excluded Licensing Transaction (in which case such prohibition shall not apply and no such consent of SFJ shall be required); provided that SFJ shall only be entitled to withhold such consent as to a Licensing Transaction other than an Excluded Licensing Transaction in the event SFJ reasonably determines, and provides PB with written notice of its determination within [***] of PB providing to SFJ a non-binding term sheet or comparable document summarizing the material terms of the proposed Licensing Transaction [***], that PB entering into such Licensing Transaction would [***] (\"Material Impact\").",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Within one hundred and twenty (120) days following the closing of a Change of Control, PB or its successor shall have the right to make a one-time payment (the \"Change of Control Buy-Out Payment\") in lieu of all (but not less than all) remaining Approval Payments for the applicable country(ies) in which Regulatory Approval has been received as of the date of closing of such Change of Control, provided that SFJ has not previously assigned the right to receive the Approval Payments to a Third Party, in which event PB or its successor shall not have such right.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Within one hundred and twenty (120) days following the closing of a Change of Control, PB or its successor shall have the right to make a one-time payment (the \"Change of Control Buy-Out Payment\") in lieu of all (but not less than all) remaining Approval Payments for the applicable country(ies) in which Regulatory Approval has been received as of the date of closing of such Change of Control, provided that SFJ has not previously assigned the right to receive the Approval Payments to a Third Party, in which event PB or its successor shall not have such right.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_0",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "PB will notify SFJ in writing promptly (and in any event within [***]) following the entering into of a definitive agreement with respect to a Change of Control of PB.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "To exercise its right to make the Change of Control Buy-Out Payment, PB or its successor shall provide written notice to SFJ (the \"Change of Control Buy-Out Notice\") no later than [***] after the date of closing of such Change of Control, which written notice shall set forth the amount of the applicable Change of",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "To exercise its right to make the Change of Control Buy-Out Payment, PB or its successor shall provide written notice to SFJ (the \"Change of Control Buy-Out Notice\") no later than [***] after the date of closing of such Change of Control, which written notice shall set forth the amount of the applicable Change of",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, any assignment of the rights or obligations under this Agreement by a Party (i) to an Affiliate shall require such Party to guarantee the performance of such Affiliate's financial and performance obligations hereunder or (ii) in connection with the sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates shall require the ultimate Affiliate controlling the other party in such transaction to guarantee such Party's financial and performance obligations hereunder and such Party shall remain liable for such financial and performance obligations notwithstanding such sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, any assignment of the rights or obligations under this Agreement by a Party (i) to an Affiliate shall require such Party to guarantee the performance of such Affiliate's financial and performance obligations hereunder or (ii) in connection with the sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates shall require the ultimate Affiliate controlling the other party in such transaction to guarantee such Party's financial and performance obligations hereunder and such Party shall remain liable for such financial and performance obligations notwithstanding such sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Control Buy-Out Payment, the proposed date of closing of the buy-out (which shall occur within [***] after the date of closing of such Change of Control), and the calculation of the Change of Control Buy-Out Payment in reasonable detail based upon the proposed closing date of the buy-out.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Control Buy-Out Payment, the proposed date of closing of the buy-out (which shall occur within [***] after the date of closing of such Change of Control), and the calculation of the Change of Control Buy-Out Payment in reasonable detail based upon the proposed closing date of the buy-out.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Change Of Control_0",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "FJ may, in its sole discretion, terminate this Agreement in its entirety at any time following a Change of Control of PB that occurs prior to the date of payment by PB of the final Approval Payment.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "PB shall not sell, transfer or assign, directly or indirectly, in whole or in part, any rights to receive payments of royalties or license fees with respect to the Product or the PB Intellectual Property (including any Accounts with respect to such royalties or license fees), other than to a wholly owned direct or indirect subsidiary of PB (it being understood that the foregoing shall not restrict the creation of any Permitted Lien).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "PB shall not sell, transfer or assign, directly or indirectly, in whole or in part, any rights to receive payments of royalties or license fees with respect to the Product or the PB Intellectual Property (including any Accounts with respect to such royalties or license fees), other than to a wholly owned direct or indirect subsidiary of PB (it being understood that the foregoing shall not restrict the creation of any Permitted Lien).",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Notwithstanding any of the foregoing, without the consent of PB, which consent may be withheld in PB's sole discretion, SFJ shall not sell, assign, sublicense or otherwise transfer this Agreement to an entity whose primary business is the development or commercialization of pharmaceutical or biotechnology products prior to the date of Program Transfer.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Notwithstanding any of the foregoing, without the consent of PB, which consent may be withheld in PB's sole discretion, SFJ shall not sell, assign, sublicense or otherwise transfer this Agreement to an entity whose primary business is the development or commercialization of pharmaceutical or biotechnology products prior to the date of Program Transfer.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Without the prior written consent of the other Party hereto, neither Party will sell, transfer, assign, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that either Party may assign, sublicense or transfer this Agreement and all of its rights and obligations hereunder, in their entirety, to any of its Affiliates or to a successor in connection with the sale or other transfer of all or substantially all of its business or assets to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise, and",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Without the prior written consent of the other Party hereto, neither Party will sell, transfer, assign, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that either Party may assign, sublicense or transfer this Agreement and all of its rights and obligations hereunder, in their entirety, to any of its Affiliates or to a successor in connection with the sale or other transfer of all or substantially all of its business or assets to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise, and",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Notwithstanding the foregoing, any assignment of the rights or obligations under this Agreement by a Party (i) to an Affiliate shall require such Party to guarantee the performance of such Affiliate's financial and performance obligations hereunder or (ii) in connection with the sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates shall require the ultimate Affiliate controlling the other party in such transaction to guarantee such Party's financial and performance obligations hereunder and such Party shall remain liable for such financial and performance obligations notwithstanding such sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Notwithstanding the foregoing, any assignment of the rights or obligations under this Agreement by a Party (i) to an Affiliate shall require such Party to guarantee the performance of such Affiliate's financial and performance obligations hereunder or (ii) in connection with the sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates shall require the ultimate Affiliate controlling the other party in such transaction to guarantee such Party's financial and performance obligations hereunder and such Party shall remain liable for such financial and performance obligations notwithstanding such sale or other transfer of all or substantially all of such Party's business or assets to which this Agreement relates.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Revenue/Profit Sharing_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "PB shall issue to SFJ on the Effective Date a warrant (\"Warrant\") exercisable for two million two hundred thousand (2,200,000) shares of PB common stock (\"Stock\") at an exercise price per share (\"Exercise Price\") equal to the greater of (a) five dollars ($5.00) or (b) 120% of the volume weighted average closing price of the Stock over the thirty (30) consecutive trading days ending on the last trading day immediately preceding the Effective Date and exercisable as follows: (i) one million one hundred thousand (1,100,000)\n\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020\n\n\n\n\n\nshares may be exercised at any time after the Effective Date provided that any such shares may be transferred by SFJ to its Affiliates but may not be resold by SFJ or its Affiliates until one (1) year after the Effective Date and (ii) one million one hundred thousand (1,100,000) shares may be exercised at any time after the date of Successful Phase 3 Interim Analysis",
      "page_number": 7,
      "words": [
        {
          "text": "1.1.62 \"Dispute' has the meaning ascribed to such term in Section 15.10.",
          "bbox": [
            616.0,
            334.0,
            2150.0,
            386.0
          ],
          "confidence": 0.9831107258796692
        },
        {
          "text": "1.1.63 \"Effective Date' has the meaning ascribed to such term in the Preamble..",
          "bbox": [
            616.0,
            464.0,
            2269.0,
            513.0
          ],
          "confidence": 0.9822954535484314
        },
        {
          "text": "1.1.64 \"EMA\" means the European Medicines Agency and any successor agency thereto in the EU having",
          "bbox": [
            611.0,
            587.0,
            2855.0,
            645.0
          ],
          "confidence": 0.9897122979164124
        },
        {
          "text": "substantially the same function..",
          "bbox": [
            285.0,
            663.0,
            919.0,
            707.0
          ],
          "confidence": 0.9780659675598145
        },
        {
          "text": "1.1.65 \"EU\" means the European Union or any successor union of European states thereto having a substantially",
          "bbox": [
            614.0,
            782.0,
            2967.0,
            833.0
          ],
          "confidence": 0.9800792932510376
        },
        {
          "text": "similar function.",
          "bbox": [
            279.0,
            851.0,
            600.0,
            901.0
          ],
          "confidence": 0.9989376068115234
        },
        {
          "text": "1.1.66 \"European Clinical Trial Countries\" means [***].",
          "bbox": [
            613.0,
            968.0,
            1791.0,
            1029.0
          ],
          "confidence": 0.9863900542259216
        },
        {
          "text": "1.1.67 \"Excluded Licensing Transaction\"' means (a) a license or sublicense granted to an academic collaborator,",
          "bbox": [
            614.0,
            1100.0,
            2954.0,
            1151.0
          ],
          "confidence": 0.9804080128669739
        },
        {
          "text": "service provider, contract research organization, contract manufacturer or similar Third Party that does not grant to such Third",
          "bbox": [
            277.0,
            1171.0,
            2918.0,
            1224.0
          ],
          "confidence": 0.9928486347198486
        },
        {
          "text": "Party any right to Commercialize the Product (other than, in the case of a CMO, the right to commercially manufacture PB2452 or",
          "bbox": [
            277.0,
            1237.0,
            3021.0,
            1290.0
          ],
          "confidence": 0.9917630553245544
        },
        {
          "text": "the Product on behalf of PB or its Affiliates, without any other right to Commercialize the Product), or (b) a license or sublicense",
          "bbox": [
            281.0,
            1310.0,
            2969.0,
            1354.0
          ],
          "confidence": 0.9964876770973206
        },
        {
          "text": "not involving a grant of rights to the Product (by way of example and not of limitation, a license or sublicense to develop and",
          "bbox": [
            275.0,
            1372.0,
            2880.0,
            1424.0
          ],
          "confidence": 0.9868518710136414
        },
        {
          "text": "commercialize any product based on PB's proprietary ELP technology, including PB1046 and PB1023).",
          "bbox": [
            277.0,
            1438.0,
            2472.0,
            1489.0
          ],
          "confidence": 0.99684077501297
        },
        {
          "text": "1.1.68 \"Exclusive Period\"' means, subject to the earlier termination of the AZ License, (a) in the case of the",
          "bbox": [
            616.0,
            1564.0,
            2853.0,
            1608.0
          ],
          "confidence": 0.990238606929779
        },
        {
          "text": "conduct of human clinical trials with respect to a Competing Product, the period beginning on the Effective Date and ending on",
          "bbox": [
            277.0,
            1632.0,
            2927.0,
            1683.0
          ],
          "confidence": 0.9948720335960388
        },
        {
          "text": "November 21, 2022, and (b) in the case of the sale or offer for sale of a Competing Product, the period beginning on the Effective",
          "bbox": [
            277.0,
            1698.0,
            3014.0,
            1749.0
          ],
          "confidence": 0.9956305623054504
        },
        {
          "text": "Date and ending on November 21, 2024.",
          "bbox": [
            279.0,
            1767.0,
            1149.0,
            1811.0
          ],
          "confidence": 0.9887081980705261
        },
        {
          "text": "1.1.69 \"Exercise Price'' has the meaning set forth in Section 8.1..",
          "bbox": [
            620.0,
            1888.0,
            1956.0,
            1932.0
          ],
          "confidence": 0.9813510179519653
        },
        {
          "text": "1.1.70 \"Executive Officers\"' means the executive officers of each of PB and SFJ identified on Exhibit E",
          "bbox": [
            618.0,
            2016.0,
            2770.0,
            2058.0
          ],
          "confidence": 0.9878758788108826
        },
        {
          "text": "1.1.71 \"Existing Licenses\" means: (a) the License, Development and Commercialization Agreement dated March",
          "bbox": [
            616.0,
            2138.0,
            2982.0,
            2189.0
          ],
          "confidence": 0.9920348525047302
        },
        {
          "text": "28, 2019, between PB and ImmunoForge Co., Ltd., including the ancillary agreements between such parties entered into in",
          "bbox": [
            279.0,
            2209.0,
            2867.0,
            2260.0
          ],
          "confidence": 0.9880244135856628
        },
        {
          "text": "connection therewith; and (b) the License Agreement dated April 13, 2018, between PB and [***], as amended.",
          "bbox": [
            279.0,
            2277.0,
            2661.0,
            2326.0
          ],
          "confidence": 0.9924896359443665
        },
        {
          "text": "1.1.72 *Existing PB Intellectual Property\"' has the meaning ascribed to such term in Section 11.1.1.1.",
          "bbox": [
            614.0,
            2397.0,
            2728.0,
            2449.0
          ],
          "confidence": 0.9812360405921936
        },
        {
          "text": "1.1.73 \"Exploit\"' has the meaning ascribed to such term in the AZ License..",
          "bbox": [
            614.0,
            2524.0,
            2162.0,
            2575.0
          ],
          "confidence": 0.9793530106544495
        },
        {
          "text": "1.1.74 *FDA\" means the US Food and Drug Administration and any successor agency thereto in the US having.",
          "bbox": [
            614.0,
            2650.0,
            2962.0,
            2705.0
          ],
          "confidence": 0.9753497838973999
        },
        {
          "text": "substantially the same function..",
          "bbox": [
            285.0,
            2726.0,
            919.0,
            2768.0
          ],
          "confidence": 0.9849979281425476
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9935910701751709
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Revenue/Profit Sharing_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "PB shall issue to SFJ on the Effective Date a warrant (\"Warrant\") exercisable for two million two hundred thousand (2,200,000) shares of PB common stock (\"Stock\") at an exercise price per share (\"Exercise Price\") equal to the greater of (a) five dollars ($5.00) or (b) 120% of the volume weighted average closing price of the Stock over the thirty (30) consecutive trading days ending on the last trading day immediately preceding the Effective Date and exercisable as follows: (i) one million one hundred thousand (1,100,000)\n\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020\n\n\n\n\n\nshares may be exercised at any time after the Effective Date provided that any such shares may be transferred by SFJ to its Affiliates but may not be resold by SFJ or its Affiliates until one (1) year after the Effective Date and (ii) one million one hundred thousand (1,100,000) shares may be exercised at any time after the date of Successful Phase 3 Interim Analysis",
      "page_number": 8,
      "words": [
        {
          "text": "1.1.75 'FFDCA' means the US Food, Drug, and Cosmetic Act, as amended from time to time, together with any.",
          "bbox": [
            614.0,
            340.0,
            3003.0,
            393.0
          ],
          "confidence": 0.9826403856277466
        },
        {
          "text": "rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications.",
          "bbox": [
            277.0,
            411.0,
            2911.0,
            462.0
          ],
          "confidence": 0.9906312227249146
        },
        {
          "text": "thereto).",
          "bbox": [
            273.0,
            475.0,
            457.0,
            530.0
          ],
          "confidence": 0.9598467946052551
        },
        {
          "text": "1.1.76 \"Financial Disclosure Form\"' has the meaning ascribed to such term in Section 3.2.1.4",
          "bbox": [
            618.0,
            603.0,
            2566.0,
            647.0
          ],
          "confidence": 0.9798718094825745
        },
        {
          "text": "1.1.77 \"GAAP\" means generally accepted accounting principles in the US, as consistently applied by the.",
          "bbox": [
            613.0,
            724.0,
            2811.0,
            780.0
          ],
          "confidence": 0.9763611555099487
        },
        {
          "text": "applicable Party.",
          "bbox": [
            281.0,
            797.0,
            624.0,
            852.0
          ],
          "confidence": 0.9815285801887512
        },
        {
          "text": "1.1.78 \"Generic Ticagrelor Product' means an oral formulation of the Ticagrelor Compound that is (a) sold,.",
          "bbox": [
            616.0,
            921.0,
            2866.0,
            970.0
          ],
          "confidence": 0.9915210604667664
        },
        {
          "text": "offered for sale or distributed under: (i) in the U.S., an ANDA (as defined in the FFDCA) that refers to the AstraZeneca Product",
          "bbox": [
            279.0,
            990.0,
            2985.0,
            1036.0
          ],
          "confidence": 0.9910622835159302
        },
        {
          "text": "as the reference listed drug, (ii) in the EU, a marketing authorization for a generic medicinal product granted in accordance with",
          "bbox": [
            277.0,
            1056.0,
            2938.0,
            1107.0
          ],
          "confidence": 0.9911012053489685
        },
        {
          "text": "Article 10 of Directive 2001/83/EC or (ii) in any other country or jurisdiction, an equivalent of provisions set forth in clause (i) or",
          "bbox": [
            277.0,
            1122.0,
            2983.0,
            1175.0
          ],
          "confidence": 0.9937861561775208
        },
        {
          "text": "clause (ii) and (b) approved in the applicable country or jurisdiction for at least one of the indications for which the AstraZeneca",
          "bbox": [
            281.0,
            1193.0,
            2953.0,
            1237.0
          ],
          "confidence": 0.9879140257835388
        },
        {
          "text": "Product is approved in such country or jurisdiction. For purposes of this definition, references to AstraZeneca Product exclude.",
          "bbox": [
            277.0,
            1254.0,
            2940.0,
            1310.0
          ],
          "confidence": 0.9939025640487671
        },
        {
          "text": "Generic Ticagrelor Products",
          "bbox": [
            279.0,
            1325.0,
            877.0,
            1371.0
          ],
          "confidence": 0.9996490478515625
        },
        {
          "text": "1.1.79 \"GMP Manufacturer\"' means the Party that is responsible for ensuring that the Product is manufactured in",
          "bbox": [
            618.0,
            1449.0,
            2960.0,
            1493.0
          ],
          "confidence": 0.9867721199989319
        },
        {
          "text": "accordance with GMP.",
          "bbox": [
            283.0,
            1519.0,
            761.0,
            1561.0
          ],
          "confidence": 0.9986399412155151
        },
        {
          "text": "1.1.80 \"Going Concern Cure Period\" has the meaning ascribed to such term in Section 3.18.3.",
          "bbox": [
            618.0,
            1639.0,
            2599.0,
            1688.0
          ],
          "confidence": 0.9835705757141113
        },
        {
          "text": "1.1.81 \"Going Concern Funding\" has the meaning ascribed to such term in Section 4.2.4..",
          "bbox": [
            618.0,
            1767.0,
            2480.0,
            1811.0
          ],
          "confidence": 0.9843544960021973
        },
        {
          "text": "1.1.82 \"Going Concern Notice\"' has the meaning ascribed to such term in Section 3.18.3..",
          "bbox": [
            616.0,
            1891.0,
            2489.0,
            1941.0
          ],
          "confidence": 0.9804561138153076
        },
        {
          "text": "1.1.83 \"Good Clinical Practices\" or \"GCP\" means all applicable good clinical practice standards for the design,",
          "bbox": [
            613.0,
            2012.0,
            2949.0,
            2072.0
          ],
          "confidence": 0.9862267971038818
        },
        {
          "text": "conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (a) the",
          "bbox": [
            283.0,
            2092.0,
            2904.0,
            2136.0
          ],
          "confidence": 0.994250476360321
        },
        {
          "text": "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (\"ICH')",
          "bbox": [
            277.0,
            2153.0,
            3016.0,
            2204.0
          ],
          "confidence": 0.9894741177558899
        },
        {
          "text": "Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical.",
          "bbox": [
            275.0,
            2220.0,
            2858.0,
            2271.0
          ],
          "confidence": 0.9895027279853821
        },
        {
          "text": "practice for clinical trials on medicinal products; (b) the Declaration of Helsinki (2004) as last amended at the 52nd World Medical",
          "bbox": [
            277.0,
            2284.0,
            3020.0,
            2339.0
          ],
          "confidence": 0.9924813508987427
        },
        {
          "text": "Association in October 2o00 and any further amendments or clarifications thereto; and (c) the equivalent Applicable Laws in any..",
          "bbox": [
            277.0,
            2352.0,
            2980.0,
            2407.0
          ],
          "confidence": 0.9796800017356873
        },
        {
          "text": "relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things.",
          "bbox": [
            275.0,
            2419.0,
            3005.0,
            2474.0
          ],
          "confidence": 0.9912734031677246
        },
        {
          "text": "assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of",
          "bbox": [
            277.0,
            2491.0,
            3011.0,
            2540.0
          ],
          "confidence": 0.9935696125030518
        },
        {
          "text": "clinical trial Subjects",
          "bbox": [
            279.0,
            2554.0,
            711.0,
            2604.0
          ],
          "confidence": 0.9773121476173401
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9866588711738586
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Minimum Commitment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "In connection with the Development, manufacture and Commercialization of the Product and fulfillment of PB's obligations hereunder, PB shall spend at least an amount equal to the amount of funding paid by SFJ to PB pursuant to this Section 4.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Minimum Commitment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "In connection with the Development, manufacture and Commercialization of the Product and fulfillment of PB's obligations hereunder, PB shall spend at least an amount equal to the amount of funding paid by SFJ to PB pursuant to this Section 4.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In consideration of the Approval Payments to be made under this Agreement (if and to the extent applicable), and in further consideration of the payment by PB to SFJ of [***], SFJ shall sell and transfer to PB, and PB shall acquire from SFJ, the sole and exclusive ownership, even as to SFJ, of the Trial Data Package including all Research Results as set forth below in this Section 11.1.1.4.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In consideration of the Approval Payments to be made under this Agreement (if and to the extent applicable), and in further consideration of the payment by PB to SFJ of [***], SFJ shall sell and transfer to PB, and PB shall acquire from SFJ, the sole and exclusive ownership, even as to SFJ, of the Trial Data Package including all Research Results as set forth below in this Section 11.1.1.4.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "effective as of such termination, SFJ shall, and it hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all Product Filings then owned or Controlled by SFJ or any of its Affiliates; provided that if any such Product Filing is not immediately transferable in a country, SFJ shall provide PB with all benefit of such Product Filing and such assistance and cooperation as necessary or reasonably requested by PB to timely transfer such Product Filing to PB or its designee or, at PB's option, to enable PB to obtain a substitute for such Product Filing without disruption to PB's development or Commercialization of the Product in the SFJ Territory;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "effective as of such termination, SFJ shall, and it hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all Product Filings then owned or Controlled by SFJ or any of its Affiliates; provided that if any such Product Filing is not immediately transferable in a country, SFJ shall provide PB with all benefit of such Product Filing and such assistance and cooperation as necessary or reasonably requested by PB to timely transfer such Product Filing to PB or its designee or, at PB's option, to enable PB to obtain a substitute for such Product Filing without disruption to PB's development or Commercialization of the Product in the SFJ Territory;",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall, and hereby does, assign to MedImmune and will cause each of its officers, directors, employees and Affiliates, and its and their respective Permitted Third Parties, to assign to MedImmune all right, title and interest in and to all Patents filed by or on behalf of PB claiming any Licensed Know-How, without additional compensation, as is necessary to fully effect the",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall, and hereby does, assign to MedImmune and will cause each of its officers, directors, employees and Affiliates, and its and their respective Permitted Third Parties, to assign to MedImmune all right, title and interest in and to all Patents filed by or on behalf of PB claiming any Licensed Know-How, without additional compensation, as is necessary to fully effect the",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "sole ownership provided for in the second sentence of this Section 11.1.1.1(b).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ acknowledges and agrees that, as required by the AZ License, MedImmune shall own and retain all right, title and interest in and to any and all AstraZeneca Product Improvements, AstraZeneca Product Know-How and AstraZeneca Product Patents.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ acknowledges and agrees that, as required by the AZ License, MedImmune shall own and retain all right, title and interest in and to any and all AstraZeneca Product Improvements, AstraZeneca Product Know-How and AstraZeneca Product Patents.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Within [***] after assignment of such Product Filings in the applicable country, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates), and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Within [***] after assignment of such Product Filings in the applicable country, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates), and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "within [***] after assignment of the Product Filings pursuant to Section 14.3.2, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates),",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "within [***] after assignment of the Product Filings pursuant to Section 14.3.2, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates),",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall cause each employee, individual consultant and Third Party contractor that SFJ or its Affiliate proposes to engage to conduct any Clinical Trial activity under or in connection with this Agreement (including, if applicable, in connection with the Program Transfer Agreement) on its behalf who conceives, discovers, develops or otherwise makes any AstraZeneca Product Improvement under or in connection with activities conducted pursuant to this Agreement to be under an obligation to assign to PB their rights in any such AstraZeneca Product Improvement, so that PB may comply with its obligations with respect to AstraZeneca Improvements, AstraZeneca Product Know-How and AstraZeneca Product Patents under the AZ License.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall cause each employee, individual consultant and Third Party contractor that SFJ or its Affiliate proposes to engage to conduct any Clinical Trial activity under or in connection with this Agreement (including, if applicable, in connection with the Program Transfer Agreement) on its behalf who conceives, discovers, develops or otherwise makes any AstraZeneca Product Improvement under or in connection with activities conducted pursuant to this Agreement to be under an obligation to assign to PB their rights in any such AstraZeneca Product Improvement, so that PB may comply with its obligations with respect to AstraZeneca Improvements, AstraZeneca Product Know-How and AstraZeneca Product Patents under the AZ License.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "to the extent not previously assigned to PB pursuant to Section 11.1.1.4, SFJ shall, and it hereby does, assign sole and exclusive ownership of the Trial Data Package including the Research Results included therein to PB, such assignment to be effective in accordance with Section 11.1.1.4;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "to the extent not previously assigned to PB pursuant to Section 11.1.1.4, SFJ shall, and it hereby does, assign sole and exclusive ownership of the Trial Data Package including the Research Results included therein to PB, such assignment to be effective in accordance with Section 11.1.1.4;",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall cause each employee and individual consultant of such SFJ or its Affiliates (but excluding Permitted Third Parties of SFJ and its Affiliates, which are separately addressed in Section 11.1.1.3(c)) who conceives, discovers, develops or otherwise makes any Trial Invention to be under an obligation to assign to PB their rights in any such Trial Invention.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall cause each employee and individual consultant of such SFJ or its Affiliates (but excluding Permitted Third Parties of SFJ and its Affiliates, which are separately addressed in Section 11.1.1.3(c)) who conceives, discovers, develops or otherwise makes any Trial Invention to be under an obligation to assign to PB their rights in any such Trial Invention.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In addition, during the Term, PB shall not take any action to terminate the AZ License without providing [***] prior written notice to SFJ of PB's intent to terminate so that SFJ may, in its sole discretion, elect to obtain the Program Transfer, and if SFJ elects in writing within such [***] period to obtain the Program Transfer, then PB shall not terminate the AZ License but shall assign it to SFJ in accordance with the Program Transfer Agreement and in such event PB shall not be entitled to any royalty payments as set forth in Section 3 of the Program Transfer Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In addition, during the Term, PB shall not take any action to terminate the AZ License without providing [***] prior written notice to SFJ of PB's intent to terminate so that SFJ may, in its sole discretion, elect to obtain the Program Transfer, and if SFJ elects in writing within such [***] period to obtain the Program Transfer, then PB shall not terminate the AZ License but shall assign it to SFJ in accordance with the Program Transfer Agreement and in such event PB shall not be entitled to any royalty payments as set forth in Section 3 of the Program Transfer Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ, for itself and on behalf of its Affiliates, hereby assigns, and shall cause such other Permitted Third Parties to assign (subject to Section 11.1.1.3(c)), to PB all its right, title and interest in and to Trial Inventions and all information and data necessary to support the filing of patent applications Covering such Trial Inventions.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ, for itself and on behalf of its Affiliates, hereby assigns, and shall cause such other Permitted Third Parties to assign (subject to Section 11.1.1.3(c)), to PB all its right, title and interest in and to Trial Inventions and all information and data necessary to support the filing of patent applications Covering such Trial Inventions.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall, and hereby does, assign to MedImmune and will cause each of its officers, directors, employees and Affiliates, and its and their respective Permitted Third Parties, to assign to MedImmune all right, title and interest in and to all (i) AstraZeneca Product Improvements that are conceived, discovered, developed or otherwise made by or on behalf of SFJ or any of its Affiliates (including by any of their respective Third Party contractors), (ii) AstraZeneca Product Know-How generated by or on behalf of SFJ or any of its Affiliates (including by any of their respective Third Party contractors), and (iii) AstraZeneca Product Patents claiming any such AstraZeneca Product Improvement(s) or AstraZeneca Product Know-How; in each case, without additional compensation, as is necessary to fully effect the sole ownership provided for in the first sentence of this Section 11.1.1.2(a).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "SFJ shall, and hereby does, assign to MedImmune and will cause each of its officers, directors, employees and Affiliates, and its and their respective Permitted Third Parties, to assign to MedImmune all right, title and interest in and to all (i) AstraZeneca Product Improvements that are conceived, discovered, developed or otherwise made by or on behalf of SFJ or any of its Affiliates (including by any of their respective Third Party contractors), (ii) AstraZeneca Product Know-How generated by or on behalf of SFJ or any of its Affiliates (including by any of their respective Third Party contractors), and (iii) AstraZeneca Product Patents claiming any such AstraZeneca Product Improvement(s) or AstraZeneca Product Know-How; in each case, without additional compensation, as is necessary to fully effect the sole ownership provided for in the first sentence of this Section 11.1.1.2(a).",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Upon approval of a BLA for the Product for the Indication by NMPA in China or PMDA in Japan, SFJ, on behalf of itself and its Affiliates, shall, and hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all INDs, BLAs and Regulatory Approvals (including all amendments and supplements to any of the foregoing) and other filings with, and formal submissions to, NMPA or PMDA, respectively, and other applicable Regulatory Authorities in such country, in each case, with respect to the Product in such country (collectively, \"Product Filings\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Upon approval of a BLA for the Product for the Indication by NMPA in China or PMDA in Japan, SFJ, on behalf of itself and its Affiliates, shall, and hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all INDs, BLAs and Regulatory Approvals (including all amendments and supplements to any of the foregoing) and other filings with, and formal submissions to, NMPA or PMDA, respectively, and other applicable Regulatory Authorities in such country, in each case, with respect to the Product in such country (collectively, \"Product Filings\").",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee;",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__License Grant_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "In the case of any individual consultant of SFJ or its Affiliates (excluding SFJ's and its Affiliates' Permitted Third Parties), if SFJ is unable to cause such consultant to agree to such assignment obligation despite SFJ's using commercially reasonable efforts to negotiate such assignment obligation, then SFJ shall either: (A) cause such consultant to grant an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, under their rights in such Trial Invention to develop, make, have made, use, sell, have sold, offer for sale and import the Product for any and all uses, except where Applicable Law requires otherwise and except in the case of consultants who are employed by governmental, not- for-profit, or public institutions that have standard policies against such an assignment (in which case, SFJ shall use commercially reasonable efforts to obtain a suitable license, or right to obtain such a license); or (B) refrain from using such consultant to conduct activities pursuant to this Agreement unless PB obtains MedImmune's written consent thereto.",
      "page_number": 3,
      "words": [
        {
          "text": "immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at",
          "bbox": [
            283.0,
            345.0,
            2992.0,
            389.0
          ],
          "confidence": 0.9966195821762085
        },
        {
          "text": "least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of",
          "bbox": [
            281.0,
            413.0,
            2972.0,
            457.0
          ],
          "confidence": 0.9941709041595459
        },
        {
          "text": "the surviving entity immediately after such merger, reorganization or consolidation, (b) a transaction in which a Third Party becomes",
          "bbox": [
            279.0,
            477.0,
            3027.0,
            526.0
          ],
          "confidence": 0.9948112964630127
        },
        {
          "text": "the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of PB, other than",
          "bbox": [
            281.0,
            545.0,
            2962.0,
            588.0
          ],
          "confidence": 0.9884380102157593
        },
        {
          "text": "through the issuance of voting securities for the purpose of raising financing to one or more financial or institutional investors that",
          "bbox": [
            277.0,
            607.0,
            2951.0,
            658.0
          ],
          "confidence": 0.9930377006530762
        },
        {
          "text": "are not then controlled by an entity engaged in the development or commercialization of pharmaceutical or biotechnology products.",
          "bbox": [
            281.0,
            680.0,
            3016.0,
            724.0
          ],
          "confidence": 0.9945303797721863
        },
        {
          "text": "or (c) the sale or other transfer of all or substantially all of PB's business or assets relating to the Product for use in the Indication.",
          "bbox": [
            281.0,
            742.0,
            2978.0,
            789.0
          ],
          "confidence": 0.9938036203384399
        },
        {
          "text": "A Licensing Transaction shall not constitute a Change of Control, unless such Licensing Transaction includes the grant of US",
          "bbox": [
            283.0,
            811.0,
            2869.0,
            855.0
          ],
          "confidence": 0.9938583374023438
        },
        {
          "text": "Commercialization Rights in which event such Licensing Transaction shall be deemed to be a Change in Control.",
          "bbox": [
            279.0,
            875.0,
            2626.0,
            925.0
          ],
          "confidence": 0.9910343885421753
        },
        {
          "text": "1.1.26 \"Change of Control Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.2",
          "bbox": [
            618.0,
            998.0,
            2762.0,
            1042.0
          ],
          "confidence": 0.9888197779655457
        },
        {
          "text": "1.1.27 \"Claim\"' means any Third Party claim, demand, suit and/or cause of action..",
          "bbox": [
            614.0,
            1122.0,
            2322.0,
            1171.0
          ],
          "confidence": 0.973606288433075
        },
        {
          "text": "1.1.28 \"Clinical Investigator' means the principal investigator at each Site..",
          "bbox": [
            618.0,
            1250.0,
            2157.0,
            1299.0
          ],
          "confidence": 0.9836348295211792
        },
        {
          "text": "1.1.29 \"Clinical Investigator Meeting\"' has the meaning ascribed to such term in Section 3.2.2.1.",
          "bbox": [
            613.0,
            1370.0,
            2623.0,
            1427.0
          ],
          "confidence": 0.9799399375915527
        },
        {
          "text": "1.1.30 \"Clinical Supply Agreement\" has the meaning ascribed to such term in Section 3.14.1.2..",
          "bbox": [
            618.0,
            1504.0,
            2608.0,
            1548.0
          ],
          "confidence": 0.9876052141189575
        },
        {
          "text": "1.1.31 \"Clinical Supply Agreement' has the meaning ascribed to such term in Section 3.14.1.1..",
          "bbox": [
            616.0,
            1628.0,
            2614.0,
            1678.0
          ],
          "confidence": 0.989601731300354
        },
        {
          "text": "1.1.32 \"Clinical Trials\"' means the Phase 3 Trial, any required supplemental clinical trial of the Product in China",
          "bbox": [
            616.0,
            1756.0,
            2922.0,
            1805.0
          ],
          "confidence": 0.9894689321517944
        },
        {
          "text": "contemplated by the Development Plan, and the pharmacokinetic study of the Product in Japanese Subjects contemplated by the",
          "bbox": [
            283.0,
            1829.0,
            2980.0,
            1873.0
          ],
          "confidence": 0.992023229598999
        },
        {
          "text": "Development Plan.",
          "bbox": [
            281.0,
            1895.0,
            676.0,
            1939.0
          ],
          "confidence": 0.9894911646842957
        },
        {
          "text": "1.1.33 \"Clinical Trial Activity\"' has the meaning ascribed to such term in Section 2.3.1.",
          "bbox": [
            616.0,
            2014.0,
            2414.0,
            2063.0
          ],
          "confidence": 0.9907666444778442
        },
        {
          "text": "1.1.34 \"Clinical Trial Agreement' has the meaning ascribed to such term in Section 3.2.1.3..",
          "bbox": [
            618.0,
            2140.0,
            2527.0,
            2189.0
          ],
          "confidence": 0.9826359748840332
        },
        {
          "text": "1.1.35 \"Clinical Trials Database\"' has the meaning ascribed to such term in Section 3.5.3.1..",
          "bbox": [
            616.0,
            2264.0,
            2518.0,
            2315.0
          ],
          "confidence": 0.9898077845573425
        },
        {
          "text": "1.1.36 \"Clinical Trials Master File' has the meaning ascribed to such term in Section 3.5.4..",
          "bbox": [
            614.0,
            2390.0,
            2514.0,
            2441.0
          ],
          "confidence": 0.9892297387123108
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9978482723236084
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__License Grant_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "In the case of any individual consultant of SFJ or its Affiliates (excluding SFJ's and its Affiliates' Permitted Third Parties), if SFJ is unable to cause such consultant to agree to such assignment obligation despite SFJ's using commercially reasonable efforts to negotiate such assignment obligation, then SFJ shall either: (A) cause such consultant to grant an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, under their rights in such Trial Invention to develop, make, have made, use, sell, have sold, offer for sale and import the Product for any and all uses, except where Applicable Law requires otherwise and except in the case of consultants who are employed by governmental, not- for-profit, or public institutions that have standard policies against such an assignment (in which case, SFJ shall use commercially reasonable efforts to obtain a suitable license, or right to obtain such a license); or (B) refrain from using such consultant to conduct activities pursuant to this Agreement unless PB obtains MedImmune's written consent thereto.",
      "page_number": 4,
      "words": [
        {
          "text": "1.1.37 \"CMC\" means chemistry, manufacturing and controls.",
          "bbox": [
            616.0,
            336.0,
            1892.0,
            387.0
          ],
          "confidence": 0.9906229972839355
        },
        {
          "text": "1.1.38 \"CMC Information\" means the CMC information intended or required for the submission of an IND or",
          "bbox": [
            616.0,
            464.0,
            2929.0,
            510.0
          ],
          "confidence": 0.9926297664642334
        },
        {
          "text": "BLA.",
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ],
          "confidence": 0.9989228248596191
        },
        {
          "text": "1.1.39 \"CMO\" means contract manufacturing organization or contract development and manufacturing",
          "bbox": [
            614.0,
            654.0,
            2768.0,
            709.0
          ],
          "confidence": 0.9910363554954529
        },
        {
          "text": "organization.",
          "bbox": [
            277.0,
            723.0,
            540.0,
            781.0
          ],
          "confidence": 0.9975845813751221
        },
        {
          "text": "1.1.40 \"Commercial Launch' means, with respect to the Product and a country in the Territory, the first sale to a.",
          "bbox": [
            616.0,
            848.0,
            2971.0,
            899.0
          ],
          "confidence": 0.9816547632217407
        },
        {
          "text": "Third Party of such Product in such country after (a) Regulatory Approval and (b) in any country in which price approval is",
          "bbox": [
            281.0,
            925.0,
            2855.0,
            968.0
          ],
          "confidence": 0.984332263469696
        },
        {
          "text": "necessary or relevant for a majority of the population to obtain access to pharmaceutical products, price approval for such Product",
          "bbox": [
            275.0,
            987.0,
            3029.0,
            1038.0
          ],
          "confidence": 0.9829985499382019
        },
        {
          "text": "in such country.",
          "bbox": [
            277.0,
            1052.0,
            602.0,
            1106.0
          ],
          "confidence": 0.9959282875061035
        },
        {
          "text": "1.1.41 \"Commercialization'' or \"Commercialize\" means the commercial manufacture, marketing, promotion, sale",
          "bbox": [
            614.0,
            1175.0,
            2962.0,
            1228.0
          ],
          "confidence": 0.9898544549942017
        },
        {
          "text": "and/or distribution of the Product. For clarity, Commercialization excludes all activities associated with development and seeking",
          "bbox": [
            281.0,
            1246.0,
            2962.0,
            1294.0
          ],
          "confidence": 0.9963714480400085
        },
        {
          "text": "Regulatory Approval for the Product..",
          "bbox": [
            279.0,
            1312.0,
            1062.0,
            1363.0
          ],
          "confidence": 0.9807345271110535
        },
        {
          "text": "1.1.42 \"Commercially Reasonable Efforts\"' means with respect to the performance of activities under this",
          "bbox": [
            614.0,
            1436.0,
            2809.0,
            1486.0
          ],
          "confidence": 0.9854094982147217
        },
        {
          "text": "Agreement by a Party (as pertains to its role in conducting the Clinical Trials): reasonable, diligent, good-faith efforts to accomplish",
          "bbox": [
            277.0,
            1504.0,
            3011.0,
            1557.0
          ],
          "confidence": 0.9930388331413269
        },
        {
          "text": "such objective which are consistent with industry standards for companies of comparable size as that of such Party. \"Commercially",
          "bbox": [
            281.0,
            1577.0,
            3009.0,
            1621.0
          ],
          "confidence": 0.9955451488494873
        },
        {
          "text": "Reasonable Efforts' requires, with respect to a particular task or activity in making, using, selling, offering for sale, importing,",
          "bbox": [
            277.0,
            1639.0,
            2884.0,
            1692.0
          ],
          "confidence": 0.9913605451583862
        },
        {
          "text": "exporting, developing (including seeking regulatory approvals or applicable pricing or reimbursement approvals) or otherwise.",
          "bbox": [
            279.0,
            1705.0,
            2898.0,
            1758.0
          ],
          "confidence": 0.995408296585083
        },
        {
          "text": "commercializing the Product, that a Party: (i) promptly assign responsibility for such task or activity to specific employee(s) who.",
          "bbox": [
            279.0,
            1774.0,
            2953.0,
            1824.0
          ],
          "confidence": 0.9884916543960571
        },
        {
          "text": "are held accountable for progress and monitor such progress on an on-going basis; (ii) set and consistently seek to achieve specific",
          "bbox": [
            279.0,
            1840.0,
            3016.0,
            1889.0
          ],
          "confidence": 0.9896214604377747
        },
        {
          "text": "and meaningful objectives for carrying out such task or activity; and (iii) make and implement decisions and allocate resources.",
          "bbox": [
            281.0,
            1906.0,
            2911.0,
            1955.0
          ],
          "confidence": 0.994252622127533
        },
        {
          "text": "designed to advance progress with respect to such objectives in accordance with established timelines; provided, however, that, to",
          "bbox": [
            279.0,
            1972.0,
            3016.0,
            2023.0
          ],
          "confidence": 0.9976450800895691
        },
        {
          "text": "the extent that the performance of a Party's obligations hereunder is adversely affected by the other Party's breach in performing its",
          "bbox": [
            281.0,
            2043.0,
            3021.0,
            2087.0
          ],
          "confidence": 0.9909575581550598
        },
        {
          "text": "obligations hereunder, the impact on the first Party of such performance failure by the other Party will be taken into account in.",
          "bbox": [
            279.0,
            2105.0,
            2909.0,
            2156.0
          ],
          "confidence": 0.9834312796592712
        },
        {
          "text": "determining whether the first Party has used its Commercially Reasonable Efforts to perform any such affected obligations.",
          "bbox": [
            283.0,
            2176.0,
            2833.0,
            2220.0
          ],
          "confidence": 0.9969245195388794
        },
        {
          "text": "1.1.43 \"Competing Product\" means any agent intended to neutralize, abrogate or reverse the antiplatelet activity of",
          "bbox": [
            618.0,
            2299.0,
            3020.0,
            2343.0
          ],
          "confidence": 0.9894914627075195
        },
        {
          "text": "the Ticagrelor Compound.",
          "bbox": [
            279.0,
            2366.0,
            828.0,
            2416.0
          ],
          "confidence": 0.9743116497993469
        },
        {
          "text": "1.1.44 \"Completion Date\"' means, as to a particular Clinical Trial, the earlier of (a) the date of final database lock.",
          "bbox": [
            614.0,
            2489.0,
            2976.0,
            2538.0
          ],
          "confidence": 0.9890645742416382
        },
        {
          "text": "for such Clinical Trial and (b) the date such Clinical Trial or this Agreement is terminated.",
          "bbox": [
            281.0,
            2560.0,
            2132.0,
            2604.0
          ],
          "confidence": 0.9939261674880981
        },
        {
          "text": "1.1.45 \"Confidential Information\" of a Party means all information and materials provided and/or disclosed",
          "bbox": [
            618.0,
            2683.0,
            2847.0,
            2726.0
          ],
          "confidence": 0.9938953518867493
        },
        {
          "text": "(including in written form, electronic form or otherwise) by,",
          "bbox": [
            277.0,
            2748.0,
            1512.0,
            2805.0
          ],
          "confidence": 0.9992232918739319
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9815122485160828
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BLA.",
          "page": 4,
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "mutually agreeing to terminate the Phase 3 Trial, in either case ((x) or (y)), due to a Serious Safety Issue that was previously known, demonstrated or identified by PB as being material as of the Effective Date and the material data showing, demonstrating, or identifying such Serious Safety Issue were not included in the Data Room, disclosed in writing to SFJ or otherwise publicly known prior to the Effective Date; then, in either case ((i) or (ii)), PB will pay SFJ within [***] of the date of termination an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ, and (B) if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2 and shall be reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.7.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "mutually agreeing to terminate the Phase 3 Trial, in either case ((x) or (y)), due to a Serious Safety Issue that was previously known, demonstrated or identified by PB as being material as of the Effective Date and the material data showing, demonstrating, or identifying such Serious Safety Issue were not included in the Data Room, disclosed in writing to SFJ or otherwise publicly known prior to the Effective Date; then, in either case ((i) or (ii)), PB will pay SFJ within [***] of the date of termination an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ, and (B) if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2 and shall be reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.7.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "within [***] after assignment of the Product Filings pursuant to Section 14.3.2, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates),",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "within [***] after assignment of the Product Filings pursuant to Section 14.3.2, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates),",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that PB terminates this Agreement pursuant to this Section 14.2.5, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that PB terminates this Agreement pursuant to this Section 14.2.5, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Additionally, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that each Approval Payment (or the Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Additionally, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that each Approval Payment (or the Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Notwithstanding the foregoing, if PB terminates this Agreement pursuant to this Section 14.2.1 above based on SFJ's failure to make any payment due to PB in accordance with ARTICLE 4, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay to SFJ fifty percent (50%) of any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (or, as applicable, fifty percent (50%) of any Buy-Out Payment that PB elects to pay pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall also be adjusted as set forth in Section 6.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Notwithstanding the foregoing, if PB terminates this Agreement pursuant to this Section 14.2.1 above based on SFJ's failure to make any payment due to PB in accordance with ARTICLE 4, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay to SFJ fifty percent (50%) of any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (or, as applicable, fifty percent (50%) of any Buy-Out Payment that PB elects to pay pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall also be adjusted as set forth in Section 6.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event SFJ terminates this Agreement pursuant to this Section 14.2.5, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ within [***] of the date of termination an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event SFJ terminates this Agreement pursuant to this Section 14.2.5, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ within [***] of the date of termination an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Notwithstanding the foregoing, (A) if this Agreement terminates pursuant to this Section 14.2.7 and such termination: (i) arises as a result of gross negligence on the part of PB; or (ii) is due to (x) the applicable independent data monitoring committee recommending termination of the Phase 3 Trial or (y) PB and SFJ",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Notwithstanding the foregoing, (A) if this Agreement terminates pursuant to this Section 14.2.7 and such termination: (i) arises as a result of gross negligence on the part of PB; or (ii) is due to (x) the applicable independent data monitoring committee recommending termination of the Phase 3 Trial or (y) PB and SFJ",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.6, then, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay to SFJ within [***] of the date of termination an amount equal to one hundred fifty percent (150%) of Development Costs which were paid or incurred by SFJ. PB or its successor (whose performance shall be guaranteed by PB) shall be obligated to continue to exercise Commercially Reasonable Effort to develop the Product and seek Regulatory Approval as set forth herein following the date of such termination including the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and shall be reduced by the amount previously paid to SFJ as set forth in this Section 14.2.6.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.6, then, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay to SFJ within [***] of the date of termination an amount equal to one hundred fifty percent (150%) of Development Costs which were paid or incurred by SFJ. PB or its successor (whose performance shall be guaranteed by PB) shall be obligated to continue to exercise Commercially Reasonable Effort to develop the Product and seek Regulatory Approval as set forth herein following the date of such termination including the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and shall be reduced by the amount previously paid to SFJ as set forth in this Section 14.2.6.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that this Agreement is terminated pursuant to this Section 14.2.4, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to make any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that this Agreement is terminated pursuant to this Section 14.2.4, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to make any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Additionally, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) (except to the extent PB pays any Buy-Out Payment(s) pursuant to Section 6.7), provided that each Approval Payment (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.1.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Additionally, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) (except to the extent PB pays any Buy-Out Payment(s) pursuant to Section 6.7), provided that each Approval Payment (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.1.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee;",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "effective as of such termination, SFJ shall, and it hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all Product Filings then owned or Controlled by SFJ or any of its Affiliates; provided that if any such Product Filing is not immediately transferable in a country, SFJ shall provide PB with all benefit of such Product Filing and such assistance and cooperation as necessary or reasonably requested by PB to timely transfer such Product Filing to PB or its designee or, at PB's option, to enable PB to obtain a substitute for such Product Filing without disruption to PB's development or Commercialization of the Product in the SFJ Territory;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "effective as of such termination, SFJ shall, and it hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all Product Filings then owned or Controlled by SFJ or any of its Affiliates; provided that if any such Product Filing is not immediately transferable in a country, SFJ shall provide PB with all benefit of such Product Filing and such assistance and cooperation as necessary or reasonably requested by PB to timely transfer such Product Filing to PB or its designee or, at PB's option, to enable PB to obtain a substitute for such Product Filing without disruption to PB's development or Commercialization of the Product in the SFJ Territory;",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.8.1, then (a) in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to one hundred fifty percent (150%) of Development Costs paid or incurred to PB by SFJ prior to such termination, and (b) if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.8.1.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.8.1, then (a) in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to one hundred fifty percent (150%) of Development Costs paid or incurred to PB by SFJ prior to such termination, and (b) if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.8.1.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.10, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay to SFJ, within [***] of the date of termination, an amount equal to the Development Costs paid or incurred by SFJ plus interest at the annual rate of twenty-five percent (25%) from the date such Development Costs were paid or incurred by SFJ and, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid to SFJ as set forth in this Section 14.2.10.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.10, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay to SFJ, within [***] of the date of termination, an amount equal to the Development Costs paid or incurred by SFJ plus interest at the annual rate of twenty-five percent (25%) from the date such Development Costs were paid or incurred by SFJ and, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid to SFJ as set forth in this Section 14.2.10.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.3, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay SFJ an amount equal to fifty percent (50%) of the Approval Payments (as adjusted as set forth in Section 6.2, subject, to the extent applicable, to Sections 2.3.3 and 3.12.2) that become due and payable under ARTICLE 6 at such time as they become due and payable (if ever) pursuant to ARTICLE 6 (or, as applicable, 50% of any Buy-Out Payment that PB elects to pay pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall also be adjusted as set forth in Section 6.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.3, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay SFJ an amount equal to fifty percent (50%) of the Approval Payments (as adjusted as set forth in Section 6.2, subject, to the extent applicable, to Sections 2.3.3 and 3.12.2) that become due and payable under ARTICLE 6 at such time as they become due and payable (if ever) pursuant to ARTICLE 6 (or, as applicable, 50% of any Buy-Out Payment that PB elects to pay pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall also be adjusted as set forth in Section 6.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.9, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall pay to SFJ, within [***] of the date of termination, an amount equal to all Development Costs paid or incurred by SFJ as of the date of termination.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.9, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall pay to SFJ, within [***] of the date of termination, an amount equal to all Development Costs paid or incurred by SFJ as of the date of termination.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "SFJ shall, and shall cause its Affiliates to, promptly assign to PB or its designee any and all Clinical Trial Agreements, CRO Agreements and other Vendor Agreements to which any of them is a party and cooperate in good faith with PB to provide appropriate notice and new contact information to the applicable Sites, Clinical Investigators, CROs and other Vendors and PB shall accept such assignment of all obligations of SFJ and its Affiliates thereunder without recourse to SFJ other than any indemnification obligations which SFJ may be liable for thereunder.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "SFJ shall, and shall cause its Affiliates to, promptly assign to PB or its designee any and all Clinical Trial Agreements, CRO Agreements and other Vendor Agreements to which any of them is a party and cooperate in good faith with PB to provide appropriate notice and new contact information to the applicable Sites, Clinical Investigators, CROs and other Vendors and PB shall accept such assignment of all obligations of SFJ and its Affiliates thereunder without recourse to SFJ other than any indemnification obligations which SFJ may be liable for thereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Additionally, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.5.2.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Additionally, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.5.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that PB terminates this Agreement pursuant to this Section 14.2.8.2, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be (A) adjusted as set forth in Section 6.2, and (B) reduced by the amount of all documented out-of-pocket expenses incurred by or on behalf of PB as a result or arising out of such violation by SFJ or any of its Representatives (including any and all amounts paid by PB as penalties or fines for such violation, in settlement of legal or administrative proceedings relating to such violation, or otherwise).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that PB terminates this Agreement pursuant to this Section 14.2.8.2, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be (A) adjusted as set forth in Section 6.2, and (B) reduced by the amount of all documented out-of-pocket expenses incurred by or on behalf of PB as a result or arising out of such violation by SFJ or any of its Representatives (including any and all amounts paid by PB as penalties or fines for such violation, in settlement of legal or administrative proceedings relating to such violation, or otherwise).",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "at PB's written request and election in PB's sole discretion, SFJ shall and hereby does, and shall cause its Affiliates to either: (i) wind down in accordance with Applicable Law and observing applicable ethical and regulatory guidelines any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination, at SFJ's cost and expense; or (ii) (x) transfer control to PB of any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination and (y) continue to conduct such Clinical Trials being conducted by or on behalf of SFJ or an Affiliate as of the effective date of termination for up to [***] to enable such transfer to be completed without interruption of any such Clinical Trial, in each case ((x) and (y)), at PB's cost and expense;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "at PB's written request and election in PB's sole discretion, SFJ shall and hereby does, and shall cause its Affiliates to either: (i) wind down in accordance with Applicable Law and observing applicable ethical and regulatory guidelines any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination, at SFJ's cost and expense; or (ii) (x) transfer control to PB of any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination and (y) continue to conduct such Clinical Trials being conducted by or on behalf of SFJ or an Affiliate as of the effective date of termination for up to [***] to enable such transfer to be completed without interruption of any such Clinical Trial, in each case ((x) and (y)), at PB's cost and expense;",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that PB terminates this Agreement pursuant to this Section 14.2.2 then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that PB terminates this Agreement pursuant to this Section 14.2.2 then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Post-Termination Services_0",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event of any termination of this Agreement pursuant to Section 14.2, then, if SFJ has not caused a Program Transfer to occur pursuant to Section 3.20:",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Audit Rights_7",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "At least [***] during the Term, upon SFJ's request, Executive Officers of PB shall meet with Executive Officers of SFJ to review and discuss PB's financial condition and operations. [***].",
      "page_number": 7,
      "words": [
        {
          "text": "1.1.62 \"Dispute' has the meaning ascribed to such term in Section 15.10.",
          "bbox": [
            616.0,
            334.0,
            2150.0,
            386.0
          ],
          "confidence": 0.9831107258796692
        },
        {
          "text": "1.1.63 \"Effective Date' has the meaning ascribed to such term in the Preamble..",
          "bbox": [
            616.0,
            464.0,
            2269.0,
            513.0
          ],
          "confidence": 0.9822954535484314
        },
        {
          "text": "1.1.64 \"EMA\" means the European Medicines Agency and any successor agency thereto in the EU having",
          "bbox": [
            611.0,
            587.0,
            2855.0,
            645.0
          ],
          "confidence": 0.9897122979164124
        },
        {
          "text": "substantially the same function..",
          "bbox": [
            285.0,
            663.0,
            919.0,
            707.0
          ],
          "confidence": 0.9780659675598145
        },
        {
          "text": "1.1.65 \"EU\" means the European Union or any successor union of European states thereto having a substantially",
          "bbox": [
            614.0,
            782.0,
            2967.0,
            833.0
          ],
          "confidence": 0.9800792932510376
        },
        {
          "text": "similar function.",
          "bbox": [
            279.0,
            851.0,
            600.0,
            901.0
          ],
          "confidence": 0.9989376068115234
        },
        {
          "text": "1.1.66 \"European Clinical Trial Countries\" means [***].",
          "bbox": [
            613.0,
            968.0,
            1791.0,
            1029.0
          ],
          "confidence": 0.9863900542259216
        },
        {
          "text": "1.1.67 \"Excluded Licensing Transaction\"' means (a) a license or sublicense granted to an academic collaborator,",
          "bbox": [
            614.0,
            1100.0,
            2954.0,
            1151.0
          ],
          "confidence": 0.9804080128669739
        },
        {
          "text": "service provider, contract research organization, contract manufacturer or similar Third Party that does not grant to such Third",
          "bbox": [
            277.0,
            1171.0,
            2918.0,
            1224.0
          ],
          "confidence": 0.9928486347198486
        },
        {
          "text": "Party any right to Commercialize the Product (other than, in the case of a CMO, the right to commercially manufacture PB2452 or",
          "bbox": [
            277.0,
            1237.0,
            3021.0,
            1290.0
          ],
          "confidence": 0.9917630553245544
        },
        {
          "text": "the Product on behalf of PB or its Affiliates, without any other right to Commercialize the Product), or (b) a license or sublicense",
          "bbox": [
            281.0,
            1310.0,
            2969.0,
            1354.0
          ],
          "confidence": 0.9964876770973206
        },
        {
          "text": "not involving a grant of rights to the Product (by way of example and not of limitation, a license or sublicense to develop and",
          "bbox": [
            275.0,
            1372.0,
            2880.0,
            1424.0
          ],
          "confidence": 0.9868518710136414
        },
        {
          "text": "commercialize any product based on PB's proprietary ELP technology, including PB1046 and PB1023).",
          "bbox": [
            277.0,
            1438.0,
            2472.0,
            1489.0
          ],
          "confidence": 0.99684077501297
        },
        {
          "text": "1.1.68 \"Exclusive Period\"' means, subject to the earlier termination of the AZ License, (a) in the case of the",
          "bbox": [
            616.0,
            1564.0,
            2853.0,
            1608.0
          ],
          "confidence": 0.990238606929779
        },
        {
          "text": "conduct of human clinical trials with respect to a Competing Product, the period beginning on the Effective Date and ending on",
          "bbox": [
            277.0,
            1632.0,
            2927.0,
            1683.0
          ],
          "confidence": 0.9948720335960388
        },
        {
          "text": "November 21, 2022, and (b) in the case of the sale or offer for sale of a Competing Product, the period beginning on the Effective",
          "bbox": [
            277.0,
            1698.0,
            3014.0,
            1749.0
          ],
          "confidence": 0.9956305623054504
        },
        {
          "text": "Date and ending on November 21, 2024.",
          "bbox": [
            279.0,
            1767.0,
            1149.0,
            1811.0
          ],
          "confidence": 0.9887081980705261
        },
        {
          "text": "1.1.69 \"Exercise Price'' has the meaning set forth in Section 8.1..",
          "bbox": [
            620.0,
            1888.0,
            1956.0,
            1932.0
          ],
          "confidence": 0.9813510179519653
        },
        {
          "text": "1.1.70 \"Executive Officers\"' means the executive officers of each of PB and SFJ identified on Exhibit E",
          "bbox": [
            618.0,
            2016.0,
            2770.0,
            2058.0
          ],
          "confidence": 0.9878758788108826
        },
        {
          "text": "1.1.71 \"Existing Licenses\" means: (a) the License, Development and Commercialization Agreement dated March",
          "bbox": [
            616.0,
            2138.0,
            2982.0,
            2189.0
          ],
          "confidence": 0.9920348525047302
        },
        {
          "text": "28, 2019, between PB and ImmunoForge Co., Ltd., including the ancillary agreements between such parties entered into in",
          "bbox": [
            279.0,
            2209.0,
            2867.0,
            2260.0
          ],
          "confidence": 0.9880244135856628
        },
        {
          "text": "connection therewith; and (b) the License Agreement dated April 13, 2018, between PB and [***], as amended.",
          "bbox": [
            279.0,
            2277.0,
            2661.0,
            2326.0
          ],
          "confidence": 0.9924896359443665
        },
        {
          "text": "1.1.72 *Existing PB Intellectual Property\"' has the meaning ascribed to such term in Section 11.1.1.1.",
          "bbox": [
            614.0,
            2397.0,
            2728.0,
            2449.0
          ],
          "confidence": 0.9812360405921936
        },
        {
          "text": "1.1.73 \"Exploit\"' has the meaning ascribed to such term in the AZ License..",
          "bbox": [
            614.0,
            2524.0,
            2162.0,
            2575.0
          ],
          "confidence": 0.9793530106544495
        },
        {
          "text": "1.1.74 *FDA\" means the US Food and Drug Administration and any successor agency thereto in the US having.",
          "bbox": [
            614.0,
            2650.0,
            2962.0,
            2705.0
          ],
          "confidence": 0.9753497838973999
        },
        {
          "text": "substantially the same function..",
          "bbox": [
            285.0,
            2726.0,
            919.0,
            2768.0
          ],
          "confidence": 0.9849979281425476
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9935910701751709
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "During the Development Term, PB will conduct quality oversight inspections and audits of the manufacturing facilities for the Product in accordance with its internal policies and PB will provide SFJ with copies of such audit reports.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "During the Development Term, PB will conduct quality oversight inspections and audits of the manufacturing facilities for the Product in accordance with its internal policies and PB will provide SFJ with copies of such audit reports.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "PB shall (a) provide SFJ with quarterly unaudited financial statements and annual audited financial statements (the \"PB Financial Statements\") promptly following the availability thereof (and no later than the date filed with the SEC) and provide to SFJ on a quarterly basis concurrently with the applicable PB Financial Statements [***], (b) promptly notify SFJ of achieving the Successful Phase 3 Interim Analysis and the Phase 3 Success Criteria, and (c) on or prior to the end of each [***] during the Term [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "PB shall (a) provide SFJ with quarterly unaudited financial statements and annual audited financial statements (the \"PB Financial Statements\") promptly following the availability thereof (and no later than the date filed with the SEC) and provide to SFJ on a quarterly basis concurrently with the applicable PB Financial Statements [***], (b) promptly notify SFJ of achieving the Successful Phase 3 Interim Analysis and the Phase 3 Success Criteria, and (c) on or prior to the end of each [***] during the Term [***].",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Cap On Liability_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "THE PARTIES AGREE THAT THE LIMITATIONS SPECIFIED IN THIS SECTION 15.11 WILL APPLY EVEN IF ANY LIMITED REMEDY SPECIFIED IN THIS AGREEMENT IS FOUND TO HAVE FAILED OF ITS ESSENTIAL PURPOSE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, \"CONSEQUENTIAL DAMAGES\" WILL BE DEEMED TO INCLUDE, AND NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OF SUCH OTHER PARTY'S AFFILIATES, REPRESENTATIVES OR STOCKHOLDERS FOR ANY DAMAGES BASED ON OR MEASURED BY LOSS OF PROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY UNACHIEVED EVENT UNDER ARTICLE 6, OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE CONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "THE PARTIES AGREE THAT THE LIMITATIONS SPECIFIED IN THIS SECTION 15.11 WILL APPLY EVEN IF ANY LIMITED REMEDY SPECIFIED IN THIS AGREEMENT IS FOUND TO HAVE FAILED OF ITS ESSENTIAL PURPOSE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, \"CONSEQUENTIAL DAMAGES\" WILL BE DEEMED TO INCLUDE, AND NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OF SUCH OTHER PARTY'S AFFILIATES, REPRESENTATIVES OR STOCKHOLDERS FOR ANY DAMAGES BASED ON OR MEASURED BY LOSS OF PROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY UNACHIEVED EVENT UNDER ARTICLE 6, OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE CONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Cap On Liability_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "TO THE MAXIMUM EXTENT PERMITTED BY LAW AND NOTWITHSTANDING ANY PROVISION IN THIS AGREEMENT TO THE CONTRARY, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, RELIANCE OR PUNITIVE DAMAGES OR LOST OR IMPUTED PROFITS OR ROYALTIES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCTS LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE.",
      "page_number": 4,
      "words": [
        {
          "text": "1.1.37 \"CMC\" means chemistry, manufacturing and controls.",
          "bbox": [
            616.0,
            336.0,
            1892.0,
            387.0
          ],
          "confidence": 0.9906229972839355
        },
        {
          "text": "1.1.38 \"CMC Information\" means the CMC information intended or required for the submission of an IND or",
          "bbox": [
            616.0,
            464.0,
            2929.0,
            510.0
          ],
          "confidence": 0.9926297664642334
        },
        {
          "text": "BLA.",
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ],
          "confidence": 0.9989228248596191
        },
        {
          "text": "1.1.39 \"CMO\" means contract manufacturing organization or contract development and manufacturing",
          "bbox": [
            614.0,
            654.0,
            2768.0,
            709.0
          ],
          "confidence": 0.9910363554954529
        },
        {
          "text": "organization.",
          "bbox": [
            277.0,
            723.0,
            540.0,
            781.0
          ],
          "confidence": 0.9975845813751221
        },
        {
          "text": "1.1.40 \"Commercial Launch' means, with respect to the Product and a country in the Territory, the first sale to a.",
          "bbox": [
            616.0,
            848.0,
            2971.0,
            899.0
          ],
          "confidence": 0.9816547632217407
        },
        {
          "text": "Third Party of such Product in such country after (a) Regulatory Approval and (b) in any country in which price approval is",
          "bbox": [
            281.0,
            925.0,
            2855.0,
            968.0
          ],
          "confidence": 0.984332263469696
        },
        {
          "text": "necessary or relevant for a majority of the population to obtain access to pharmaceutical products, price approval for such Product",
          "bbox": [
            275.0,
            987.0,
            3029.0,
            1038.0
          ],
          "confidence": 0.9829985499382019
        },
        {
          "text": "in such country.",
          "bbox": [
            277.0,
            1052.0,
            602.0,
            1106.0
          ],
          "confidence": 0.9959282875061035
        },
        {
          "text": "1.1.41 \"Commercialization'' or \"Commercialize\" means the commercial manufacture, marketing, promotion, sale",
          "bbox": [
            614.0,
            1175.0,
            2962.0,
            1228.0
          ],
          "confidence": 0.9898544549942017
        },
        {
          "text": "and/or distribution of the Product. For clarity, Commercialization excludes all activities associated with development and seeking",
          "bbox": [
            281.0,
            1246.0,
            2962.0,
            1294.0
          ],
          "confidence": 0.9963714480400085
        },
        {
          "text": "Regulatory Approval for the Product..",
          "bbox": [
            279.0,
            1312.0,
            1062.0,
            1363.0
          ],
          "confidence": 0.9807345271110535
        },
        {
          "text": "1.1.42 \"Commercially Reasonable Efforts\"' means with respect to the performance of activities under this",
          "bbox": [
            614.0,
            1436.0,
            2809.0,
            1486.0
          ],
          "confidence": 0.9854094982147217
        },
        {
          "text": "Agreement by a Party (as pertains to its role in conducting the Clinical Trials): reasonable, diligent, good-faith efforts to accomplish",
          "bbox": [
            277.0,
            1504.0,
            3011.0,
            1557.0
          ],
          "confidence": 0.9930388331413269
        },
        {
          "text": "such objective which are consistent with industry standards for companies of comparable size as that of such Party. \"Commercially",
          "bbox": [
            281.0,
            1577.0,
            3009.0,
            1621.0
          ],
          "confidence": 0.9955451488494873
        },
        {
          "text": "Reasonable Efforts' requires, with respect to a particular task or activity in making, using, selling, offering for sale, importing,",
          "bbox": [
            277.0,
            1639.0,
            2884.0,
            1692.0
          ],
          "confidence": 0.9913605451583862
        },
        {
          "text": "exporting, developing (including seeking regulatory approvals or applicable pricing or reimbursement approvals) or otherwise.",
          "bbox": [
            279.0,
            1705.0,
            2898.0,
            1758.0
          ],
          "confidence": 0.995408296585083
        },
        {
          "text": "commercializing the Product, that a Party: (i) promptly assign responsibility for such task or activity to specific employee(s) who.",
          "bbox": [
            279.0,
            1774.0,
            2953.0,
            1824.0
          ],
          "confidence": 0.9884916543960571
        },
        {
          "text": "are held accountable for progress and monitor such progress on an on-going basis; (ii) set and consistently seek to achieve specific",
          "bbox": [
            279.0,
            1840.0,
            3016.0,
            1889.0
          ],
          "confidence": 0.9896214604377747
        },
        {
          "text": "and meaningful objectives for carrying out such task or activity; and (iii) make and implement decisions and allocate resources.",
          "bbox": [
            281.0,
            1906.0,
            2911.0,
            1955.0
          ],
          "confidence": 0.994252622127533
        },
        {
          "text": "designed to advance progress with respect to such objectives in accordance with established timelines; provided, however, that, to",
          "bbox": [
            279.0,
            1972.0,
            3016.0,
            2023.0
          ],
          "confidence": 0.9976450800895691
        },
        {
          "text": "the extent that the performance of a Party's obligations hereunder is adversely affected by the other Party's breach in performing its",
          "bbox": [
            281.0,
            2043.0,
            3021.0,
            2087.0
          ],
          "confidence": 0.9909575581550598
        },
        {
          "text": "obligations hereunder, the impact on the first Party of such performance failure by the other Party will be taken into account in.",
          "bbox": [
            279.0,
            2105.0,
            2909.0,
            2156.0
          ],
          "confidence": 0.9834312796592712
        },
        {
          "text": "determining whether the first Party has used its Commercially Reasonable Efforts to perform any such affected obligations.",
          "bbox": [
            283.0,
            2176.0,
            2833.0,
            2220.0
          ],
          "confidence": 0.9969245195388794
        },
        {
          "text": "1.1.43 \"Competing Product\" means any agent intended to neutralize, abrogate or reverse the antiplatelet activity of",
          "bbox": [
            618.0,
            2299.0,
            3020.0,
            2343.0
          ],
          "confidence": 0.9894914627075195
        },
        {
          "text": "the Ticagrelor Compound.",
          "bbox": [
            279.0,
            2366.0,
            828.0,
            2416.0
          ],
          "confidence": 0.9743116497993469
        },
        {
          "text": "1.1.44 \"Completion Date\"' means, as to a particular Clinical Trial, the earlier of (a) the date of final database lock.",
          "bbox": [
            614.0,
            2489.0,
            2976.0,
            2538.0
          ],
          "confidence": 0.9890645742416382
        },
        {
          "text": "for such Clinical Trial and (b) the date such Clinical Trial or this Agreement is terminated.",
          "bbox": [
            281.0,
            2560.0,
            2132.0,
            2604.0
          ],
          "confidence": 0.9939261674880981
        },
        {
          "text": "1.1.45 \"Confidential Information\" of a Party means all information and materials provided and/or disclosed",
          "bbox": [
            618.0,
            2683.0,
            2847.0,
            2726.0
          ],
          "confidence": 0.9938953518867493
        },
        {
          "text": "(including in written form, electronic form or otherwise) by,",
          "bbox": [
            277.0,
            2748.0,
            1512.0,
            2805.0
          ],
          "confidence": 0.9992232918739319
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9815122485160828
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BLA.",
          "page": 4,
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Cap On Liability_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "TO THE MAXIMUM EXTENT PERMITTED BY LAW AND NOTWITHSTANDING ANY PROVISION IN THIS AGREEMENT TO THE CONTRARY, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, RELIANCE OR PUNITIVE DAMAGES OR LOST OR IMPUTED PROFITS OR ROYALTIES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCTS LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE.",
      "page_number": 5,
      "words": [
        {
          "text": "or on behalf of, such Party or its Affiliates, agents or representatives to the other Party, its Affiliates, agents or representatives in",
          "bbox": [
            279.0,
            344.0,
            2947.0,
            389.0
          ],
          "confidence": 0.9903295040130615
        },
        {
          "text": "connection with this Agreement, including, technical, scientific, regulatory and other information, results, knowledge, techniques,",
          "bbox": [
            277.0,
            407.0,
            2945.0,
            461.0
          ],
          "confidence": 0.9954399466514587
        },
        {
          "text": "data, analyses, inventions, invention disclosures, plans, processes, methods, know-how, ideas, concepts, test data (including",
          "bbox": [
            277.0,
            475.0,
            2878.0,
            528.0
          ],
          "confidence": 0.9937788248062134
        },
        {
          "text": "pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing.",
          "bbox": [
            277.0,
            543.0,
            2860.0,
            594.0
          ],
          "confidence": 0.9927600026130676
        },
        {
          "text": "pricing, distribution, cost, sales, and manufacturing data and descriptions. In addition, the terms and conditions of this Agreement",
          "bbox": [
            277.0,
            607.0,
            2976.0,
            660.0
          ],
          "confidence": 0.9966555237770081
        },
        {
          "text": "shall be deemed to be Confidential Information of both SFJ and PB. For further clarity, the terms of the AZ License shall be",
          "bbox": [
            277.0,
            672.0,
            2875.0,
            724.0
          ],
          "confidence": 0.9866896867752075
        },
        {
          "text": "considered the Confidential Information of PB, and SFJ acknowledges that the terms of the AZ License are also considered",
          "bbox": [
            281.0,
            744.0,
            2876.0,
            788.0
          ],
          "confidence": 0.9927793741226196
        },
        {
          "text": "\"Confidential Information' (as defined in the AZ License) of MedImmune, and that each of PB and MedImmune is deemed to be",
          "bbox": [
            279.0,
            804.0,
            2987.0,
            857.0
          ],
          "confidence": 0.9931616187095642
        },
        {
          "text": "the \"receiving Party\"' and the \"disclosing Party\"' with respect thereto for purposes of the AZ License. Notwithstanding the",
          "bbox": [
            279.0,
            875.0,
            2815.0,
            925.0
          ],
          "confidence": 0.9845126867294312
        },
        {
          "text": "foregoing, any AstraZeneca Product Know-How and any AstraZeneca Product Improvement shall be deemed to be the",
          "bbox": [
            277.0,
            941.0,
            2808.0,
            994.0
          ],
          "confidence": 0.9995084404945374
        },
        {
          "text": "Confidential Information of PB for purposes of this Agreement and of MedImmune for purposes of the AZ License, and SFJ shall",
          "bbox": [
            277.0,
            1009.0,
            3000.0,
            1058.0
          ],
          "confidence": 0.9910944700241089
        },
        {
          "text": "be deemed to be the receiving Party and PB shall be deemed to be the disclosing Party with respect thereto for purposes of this",
          "bbox": [
            279.0,
            1078.0,
            2956.0,
            1122.0
          ],
          "confidence": 0.9964855909347534
        },
        {
          "text": "Agreement (it being understood that MedImmune is deemed to be the \"receiving Party'' and MedImmune is deemed to be the",
          "bbox": [
            281.0,
            1142.0,
            2916.0,
            1191.0
          ],
          "confidence": 0.9885003566741943
        },
        {
          "text": "\"disclosing Party\"' with respect thereto for purposes of the AZ License). In addition, notwithstanding SFJ's ownership of the",
          "bbox": [
            275.0,
            1204.0,
            2876.0,
            1261.0
          ],
          "confidence": 0.9822927713394165
        },
        {
          "text": "Research Results prior to assignment thereof in accordance with Section 11.1.1.4, the Research Results shall at all times be",
          "bbox": [
            279.0,
            1275.0,
            2862.0,
            1325.0
          ],
          "confidence": 0.9935576915740967
        },
        {
          "text": "deemed to be Confidential Information of PB, and PB and SFJ shall be deemed the disclosing Party and the receiving Party,",
          "bbox": [
            277.0,
            1334.0,
            2880.0,
            1396.0
          ],
          "confidence": 0.9958563446998596
        },
        {
          "text": "respectively, with respect thereto.",
          "bbox": [
            275.0,
            1409.0,
            981.0,
            1460.0
          ],
          "confidence": 0.9998310804367065
        },
        {
          "text": "1.1.46 \"Contingent Liabilities\"' means, for any Person, (i) Indebtedness (as defined in Section 7.7.3) of that",
          "bbox": [
            614.0,
            1531.0,
            2856.0,
            1581.0
          ],
          "confidence": 0.9910394549369812
        },
        {
          "text": "Person, and (ii) any direct or indirect liability, contingent or not, of that Person for (a) warranty obligations, (b) potential claims for",
          "bbox": [
            279.0,
            1603.0,
            2994.0,
            1652.0
          ],
          "confidence": 0.9992796778678894
        },
        {
          "text": "damages, (c) assessments, and (d) any other condition, situation or set of circumstances involving various degrees of uncertainty",
          "bbox": [
            277.0,
            1668.0,
            2953.0,
            1720.0
          ],
          "confidence": 0.9966703653335571
        },
        {
          "text": "that may result in a loss or liability.",
          "bbox": [
            277.0,
            1732.0,
            988.0,
            1785.0
          ],
          "confidence": 0.983894944190979
        },
        {
          "text": "1.1.47 \"Control'' or \"Controlled' means (a) for Intellectual Property, a Party's ability to grant applicable licenses.",
          "bbox": [
            613.0,
            1855.0,
            2976.0,
            1908.0
          ],
          "confidence": 0.9868646860122681
        },
        {
          "text": "sublicenses and/or other rights thereunder and (b) for materials and documents, a Party's ability to provide, or provide access to,",
          "bbox": [
            277.0,
            1926.0,
            2980.0,
            1977.0
          ],
          "confidence": 0.9957748055458069
        },
        {
          "text": "such materials and/or documents, each without violating any contractual obligations to a Third Party. For clarity, if a Party only can",
          "bbox": [
            279.0,
            1995.0,
            3007.0,
            2045.0
          ],
          "confidence": 0.9897483587265015
        },
        {
          "text": "grant a license or sublicense and/or provide rights and/or access of limited scope, for a specific purpose or under certain conditions",
          "bbox": [
            279.0,
            2061.0,
            3025.0,
            2111.0
          ],
          "confidence": 0.9985711574554443
        },
        {
          "text": "due to an encumbrance, \"Control'' or \"Controlled' will be construed to so limit such license, sublicense, provision of rights and/or",
          "bbox": [
            277.0,
            2125.0,
            2987.0,
            2176.0
          ],
          "confidence": 0.9914212226867676
        },
        {
          "text": "access.",
          "bbox": [
            276.0,
            2202.0,
            430.0,
            2240.0
          ],
          "confidence": 0.8855510950088501
        },
        {
          "text": "1.1.48 \"Copyrights\" means, collectively, all works of authorship, mask works and any and all other registered and",
          "bbox": [
            614.0,
            2313.0,
            3000.0,
            2366.0
          ],
          "confidence": 0.9891541600227356
        },
        {
          "text": "unregistered copyrights and copyrightable works, and all applications, registrations, extensions, and renewals thereof.",
          "bbox": [
            279.0,
            2385.0,
            2735.0,
            2438.0
          ],
          "confidence": 0.9995512366294861
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9838435053825378
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Cap On Liability_89",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Each Party expressly waives and foregoes any right to consequential, punitive, special, exemplary or similar damages or lost profits.",
      "page_number": 89,
      "words": [
        {
          "text": "prevailing Party's actual damages, except as may be required by statute. Each Party expressly waives and foregoes any right to",
          "bbox": [
            279.0,
            1396.0,
            2940.0,
            1445.0
          ],
          "confidence": 0.9920375943183899
        },
        {
          "text": "consequential, punitive, special, exemplary or similar damages or lost profits. The arbitrators shall have no power or authority,",
          "bbox": [
            279.0,
            1462.0,
            2909.0,
            1511.0
          ],
          "confidence": 0.9946157932281494
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Liquidated Damages_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.1 then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Liquidated Damages_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
      "answer_text": "In the event that SFJ terminates this Agreement pursuant to this Section 14.2.1 then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party will include the other Party and its Affiliates as additional insured parties on such Party's Clinical Trial Liability insurance, as set forth in Section 12.3.2.3 for [***] after the later of termination of this Agreement or release of the last Subject from the Clinical Trials.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party will include the other Party and its Affiliates as additional insured parties on such Party's Clinical Trial Liability insurance, as set forth in Section 12.3.2.3 for [***] after the later of termination of this Agreement or release of the last Subject from the Clinical Trials.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commercialization of the Product at its expense with SFJ to be named as an additional insured party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "From and after a Program Transfer, SFJ will be responsible for maintaining product liability insurance related to the Development and Commercialization of the Product at its expense with PB to be named as an additional insured party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "From and after a Program Transfer, SFJ will be responsible for maintaining product liability insurance related to the Development and Commercialization of the Product at its expense with PB to be named as an additional insured party.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Coverage must be maintained for at least [***] after the later of (i) expiration or early termination of this Agreement and (ii) release of the last Subject from the Clinical Trials.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_3",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Prior to a Program Transfer, PB will be responsible for maintaining product liability insurance related to the Development and",
      "page_number": 3,
      "words": [
        {
          "text": "immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at",
          "bbox": [
            283.0,
            345.0,
            2992.0,
            389.0
          ],
          "confidence": 0.9966195821762085
        },
        {
          "text": "least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of",
          "bbox": [
            281.0,
            413.0,
            2972.0,
            457.0
          ],
          "confidence": 0.9941709041595459
        },
        {
          "text": "the surviving entity immediately after such merger, reorganization or consolidation, (b) a transaction in which a Third Party becomes",
          "bbox": [
            279.0,
            477.0,
            3027.0,
            526.0
          ],
          "confidence": 0.9948112964630127
        },
        {
          "text": "the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of PB, other than",
          "bbox": [
            281.0,
            545.0,
            2962.0,
            588.0
          ],
          "confidence": 0.9884380102157593
        },
        {
          "text": "through the issuance of voting securities for the purpose of raising financing to one or more financial or institutional investors that",
          "bbox": [
            277.0,
            607.0,
            2951.0,
            658.0
          ],
          "confidence": 0.9930377006530762
        },
        {
          "text": "are not then controlled by an entity engaged in the development or commercialization of pharmaceutical or biotechnology products.",
          "bbox": [
            281.0,
            680.0,
            3016.0,
            724.0
          ],
          "confidence": 0.9945303797721863
        },
        {
          "text": "or (c) the sale or other transfer of all or substantially all of PB's business or assets relating to the Product for use in the Indication.",
          "bbox": [
            281.0,
            742.0,
            2978.0,
            789.0
          ],
          "confidence": 0.9938036203384399
        },
        {
          "text": "A Licensing Transaction shall not constitute a Change of Control, unless such Licensing Transaction includes the grant of US",
          "bbox": [
            283.0,
            811.0,
            2869.0,
            855.0
          ],
          "confidence": 0.9938583374023438
        },
        {
          "text": "Commercialization Rights in which event such Licensing Transaction shall be deemed to be a Change in Control.",
          "bbox": [
            279.0,
            875.0,
            2626.0,
            925.0
          ],
          "confidence": 0.9910343885421753
        },
        {
          "text": "1.1.26 \"Change of Control Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.2",
          "bbox": [
            618.0,
            998.0,
            2762.0,
            1042.0
          ],
          "confidence": 0.9888197779655457
        },
        {
          "text": "1.1.27 \"Claim\"' means any Third Party claim, demand, suit and/or cause of action..",
          "bbox": [
            614.0,
            1122.0,
            2322.0,
            1171.0
          ],
          "confidence": 0.973606288433075
        },
        {
          "text": "1.1.28 \"Clinical Investigator' means the principal investigator at each Site..",
          "bbox": [
            618.0,
            1250.0,
            2157.0,
            1299.0
          ],
          "confidence": 0.9836348295211792
        },
        {
          "text": "1.1.29 \"Clinical Investigator Meeting\"' has the meaning ascribed to such term in Section 3.2.2.1.",
          "bbox": [
            613.0,
            1370.0,
            2623.0,
            1427.0
          ],
          "confidence": 0.9799399375915527
        },
        {
          "text": "1.1.30 \"Clinical Supply Agreement\" has the meaning ascribed to such term in Section 3.14.1.2..",
          "bbox": [
            618.0,
            1504.0,
            2608.0,
            1548.0
          ],
          "confidence": 0.9876052141189575
        },
        {
          "text": "1.1.31 \"Clinical Supply Agreement' has the meaning ascribed to such term in Section 3.14.1.1..",
          "bbox": [
            616.0,
            1628.0,
            2614.0,
            1678.0
          ],
          "confidence": 0.989601731300354
        },
        {
          "text": "1.1.32 \"Clinical Trials\"' means the Phase 3 Trial, any required supplemental clinical trial of the Product in China",
          "bbox": [
            616.0,
            1756.0,
            2922.0,
            1805.0
          ],
          "confidence": 0.9894689321517944
        },
        {
          "text": "contemplated by the Development Plan, and the pharmacokinetic study of the Product in Japanese Subjects contemplated by the",
          "bbox": [
            283.0,
            1829.0,
            2980.0,
            1873.0
          ],
          "confidence": 0.992023229598999
        },
        {
          "text": "Development Plan.",
          "bbox": [
            281.0,
            1895.0,
            676.0,
            1939.0
          ],
          "confidence": 0.9894911646842957
        },
        {
          "text": "1.1.33 \"Clinical Trial Activity\"' has the meaning ascribed to such term in Section 2.3.1.",
          "bbox": [
            616.0,
            2014.0,
            2414.0,
            2063.0
          ],
          "confidence": 0.9907666444778442
        },
        {
          "text": "1.1.34 \"Clinical Trial Agreement' has the meaning ascribed to such term in Section 3.2.1.3..",
          "bbox": [
            618.0,
            2140.0,
            2527.0,
            2189.0
          ],
          "confidence": 0.9826359748840332
        },
        {
          "text": "1.1.35 \"Clinical Trials Database\"' has the meaning ascribed to such term in Section 3.5.3.1..",
          "bbox": [
            616.0,
            2264.0,
            2518.0,
            2315.0
          ],
          "confidence": 0.9898077845573425
        },
        {
          "text": "1.1.36 \"Clinical Trials Master File' has the meaning ascribed to such term in Section 3.5.4..",
          "bbox": [
            614.0,
            2390.0,
            2514.0,
            2441.0
          ],
          "confidence": 0.9892297387123108
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9978482723236084
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commencing as of the start of the Clinical Trials and thereafter, during the Term (or longer if otherwise stated below), at a minimum, each Party will maintain the following types of insurance coverage at a minimum level that is the greater of (a) the highest minimum level required by Applicable Law in the countries in which the Clinical Trials and other obligations hereunder are being performed or (b) the following (to the extent different).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commencing as of the start of the Clinical Trials and thereafter, during the Term (or longer if otherwise stated below), at a minimum, each Party will maintain the following types of insurance coverage at a minimum level that is the greater of (a) the highest minimum level required by Applicable Law in the countries in which the Clinical Trials and other obligations hereunder are being performed or (b) the following (to the extent different).",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_53_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commercial General Liability: [***] dollars ($[***]) per occurrence; [***] dollars ($[***]) Product and Completed Operations aggregate, including Premises & Operations, Personal Injury, Product and Completed Operations; [***] dollars ($[***]) combined single limit on all owned, non-owned and hired vehicles of such Party.",
      "page_number": 53,
      "words": [
        {
          "text": "replacement of the SVB Loan Agreement, enter into a new subordination agreement with a new lender(s) on terms and conditions",
          "bbox": [
            281.0,
            344.0,
            3003.0,
            387.0
          ],
          "confidence": 0.9995290040969849
        },
        {
          "text": "that are taken as a whole not less favorable in any material respect to SFJ than those set forth in the subordination agreement to be",
          "bbox": [
            281.0,
            411.0,
            3011.0,
            455.0
          ],
          "confidence": 0.9939222931861877
        },
        {
          "text": "entered into with SVB, and (d) otherwise be in form and substance reasonably satisfactory to SFJ. Upon the execution of such.",
          "bbox": [
            283.0,
            479.0,
            2936.0,
            523.0
          ],
          "confidence": 0.9922934770584106
        },
        {
          "text": "new subordination agreement with such new lender(s), references herein to \"SVB'' shall refer to such new lender(s), references",
          "bbox": [
            281.0,
            545.0,
            2938.0,
            588.0
          ],
          "confidence": 0.9916369915008545
        },
        {
          "text": "herein to the \"SVB Loan'' shall refer to the loans provided by such new lender (provided that the aggregate principal amount of",
          "bbox": [
            275.0,
            607.0,
            2951.0,
            660.0
          ],
          "confidence": 0.9973737001419067
        },
        {
          "text": "such loans shall not exceed [***D), references herein to the \"SVB Collateral' shall refer to the collateral securing such new loan,",
          "bbox": [
            279.0,
            676.0,
            2962.0,
            725.0
          ],
          "confidence": 0.9819372296333313
        },
        {
          "text": "and references herein to the \"SVB Loan Agreement' shall refer to such loan and security agreement or similar document entered",
          "bbox": [
            279.0,
            740.0,
            2973.0,
            791.0
          ],
          "confidence": 0.9842204451560974
        },
        {
          "text": "into with such new lender(s)..",
          "bbox": [
            279.0,
            808.0,
            874.0,
            855.0
          ],
          "confidence": 0.9782766699790955
        },
        {
          "text": "7.5 Negative Covenants.",
          "bbox": [
            448.0,
            928.0,
            963.0,
            978.0
          ],
          "confidence": 0.9985463619232178
        },
        {
          "text": "7.5.1 Incurrence of Certain Indebtedness. PB shall not, without SFJ's prior written consent, create, incur, assume,.",
          "bbox": [
            613.0,
            1054.0,
            3005.0,
            1109.0
          ],
          "confidence": 0.9908298254013062
        },
        {
          "text": "or be liable for any Indebtedness, or permit any subsidiary of PB to do so, other than Permitted Indebtedness..",
          "bbox": [
            281.0,
            1127.0,
            2585.0,
            1177.0
          ],
          "confidence": 0.9912606477737427
        },
        {
          "text": "7.5.2 Subordinated Debt. PB shall not (a) make or permit any payment on any Subordinated Debt, except to the",
          "bbox": [
            613.0,
            1246.0,
            2985.0,
            1303.0
          ],
          "confidence": 0.9934866428375244
        },
        {
          "text": "extent permitted by the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is",
          "bbox": [
            279.0,
            1317.0,
            2944.0,
            1371.0
          ],
          "confidence": 0.9968878626823425
        },
        {
          "text": "subject, or (b) amend any provision in any document relating to Subordinated Debt which would provide for earlier or greater",
          "bbox": [
            283.0,
            1391.0,
            2918.0,
            1434.0
          ],
          "confidence": 0.9900172352790833
        },
        {
          "text": "principal, interest, or other cash payments thereon, or materially adversely affect the subordination thereof to PB Obligations owed",
          "bbox": [
            277.0,
            1451.0,
            3016.0,
            1506.0
          ],
          "confidence": 0.9931237101554871
        },
        {
          "text": "to SFJ.",
          "bbox": [
            269.0,
            1514.0,
            434.0,
            1574.0
          ],
          "confidence": 0.9853449463844299
        },
        {
          "text": "7.5.3 Encumbrances. PB shall not, without SFJ's prior written consent:",
          "bbox": [
            614.0,
            1641.0,
            2101.0,
            1692.0
          ],
          "confidence": 0.9925510883331299
        },
        {
          "text": "7.5.3.1 create, incur, allow, or suffer any Lien on any of the PB Intellectual Property, or assign or convey",
          "bbox": [
            783.0,
            1765.0,
            2976.0,
            1822.0
          ],
          "confidence": 0.9903187155723572
        },
        {
          "text": "any right to receive income with respect to the PB Intellectual Property (other than royalty and other license fee obligations to",
          "bbox": [
            281.0,
            1840.0,
            2907.0,
            1889.0
          ],
          "confidence": 0.9965915083885193
        },
        {
          "text": "licensors thereof in accordance with the applicable license agreement), including the sale of any PB Intellectual Property, or permit",
          "bbox": [
            279.0,
            1908.0,
            3003.0,
            1957.0
          ],
          "confidence": 0.996095597743988
        },
        {
          "text": "any of its subsidiaries to do so, other than Liens in favor of SVB (subject in all respects to the terms and conditions of the.",
          "bbox": [
            281.0,
            1974.0,
            2820.0,
            2017.0
          ],
          "confidence": 0.9919012784957886
        },
        {
          "text": "subordination agreement contemplated by Section 7.4 hereof) and other Permitted Liens that are permitted pursuant to the terms",
          "bbox": [
            281.0,
            2043.0,
            2976.0,
            2087.0
          ],
          "confidence": 0.9981175065040588
        },
        {
          "text": "of this Agreement; or.",
          "bbox": [
            279.0,
            2105.0,
            727.0,
            2160.0
          ],
          "confidence": 0.9746027588844299
        },
        {
          "text": "7.5.3.2 except as and to the extent permitted by Section 7.5.6, enter into any agreement, document,",
          "bbox": [
            783.0,
            2228.0,
            2882.0,
            2281.0
          ],
          "confidence": 0.9777225255966187
        },
        {
          "text": "instrument or other arrangement (except with or in favor of SFJ or SVB) with any Person which directly or indirectly prohibits or",
          "bbox": [
            277.0,
            2301.0,
            2980.0,
            2350.0
          ],
          "confidence": 0.9925428032875061
        },
        {
          "text": "has the effect of prohibiting PB or any subsidiary of PB from assigning, mortgaging, pledging, granting a security interest in or upon.",
          "bbox": [
            274.0,
            2361.0,
            3011.0,
            2423.0
          ],
          "confidence": 0.9857593774795532
        },
        {
          "text": "or encumbering any proceeds from PB Intellectual Property..",
          "bbox": [
            277.0,
            2430.0,
            1542.0,
            2485.0
          ],
          "confidence": 0.9899924993515015
        },
        {
          "text": "7.5.4 Distributions; Investments. PB shall not, without SFJ's prior written consent, (a) pay any dividends or make.",
          "bbox": [
            613.0,
            2553.0,
            2992.0,
            2606.0
          ],
          "confidence": 0.9896194934844971
        },
        {
          "text": "any distribution or payment on account of or redeem, retire or purchase any capital stock, provided that (i) PB may convert any of.",
          "bbox": [
            279.0,
            2624.0,
            3021.0,
            2675.0
          ],
          "confidence": 0.989717423915863
        },
        {
          "text": "its equity convertible securities into other equity securities (or cash for partial shares) pursuant to the terms of such equity",
          "bbox": [
            275.0,
            2688.0,
            2804.0,
            2747.0
          ],
          "confidence": 0.9929426908493042
        },
        {
          "text": "convertible securities or otherwise in exchange thereof, (ii) PB may pay dividends",
          "bbox": [
            281.0,
            2759.0,
            1986.0,
            2809.0
          ],
          "confidence": 0.9995732307434082
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9866588711738586
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_54_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commercial General Liability: [***] dollars ($[***]) per occurrence; [***] dollars ($[***]) Product and Completed Operations aggregate, including Premises & Operations, Personal Injury, Product and Completed Operations; [***] dollars ($[***]) combined single limit on all owned, non-owned and hired vehicles of such Party.",
      "page_number": 54,
      "words": [
        {
          "text": "solely in common stock, and (iii) PB may repurchase the stock of former employees or consultants pursuant to stock repurchase",
          "bbox": [
            281.0,
            345.0,
            2965.0,
            389.0
          ],
          "confidence": 0.9907211661338806
        },
        {
          "text": "agreements, provided that the aggregate amount of all such repurchases does not exceed [***] Dollars ($[***]) per fiscal year, or",
          "bbox": [
            276.0,
            404.0,
            3020.0,
            464.0
          ],
          "confidence": 0.991024374961853
        },
        {
          "text": "(b) directly or indirectly make any Prohibited Investment (including, without limitation, by the formation of or through any",
          "bbox": [
            279.0,
            477.0,
            2806.0,
            528.0
          ],
          "confidence": 0.9927078485488892
        },
        {
          "text": "subsidiary), or permit any of its subsidiaries to do so. For the avoidance of doubt, nothing in this Section 7.5.4 shall limit the ability",
          "bbox": [
            281.0,
            543.0,
            3000.0,
            592.0
          ],
          "confidence": 0.9885690808296204
        },
        {
          "text": "of PB to pay or settle on conversion (in cash or equity) any convertible indebtedness.",
          "bbox": [
            281.0,
            612.0,
            2061.0,
            656.0
          ],
          "confidence": 0.9973058700561523
        },
        {
          "text": "7.5.5 Licensing Transactions. PB shall have the right, without SFJ's consent, to enter into any Excluded Licensing",
          "bbox": [
            614.0,
            725.0,
            2987.0,
            786.0
          ],
          "confidence": 0.9927489757537842
        },
        {
          "text": "Transaction. PB shall not, without SFJ's prior written consent, enter into a Licensing Transaction unless such Licensing Transaction",
          "bbox": [
            277.0,
            802.0,
            3007.0,
            848.0
          ],
          "confidence": 0.987877607345581
        },
        {
          "text": "is an Excluded Licensing Transaction (in which case such prohibition shall not apply and no such consent of SFJ shall be required);.",
          "bbox": [
            274.0,
            862.0,
            3011.0,
            921.0
          ],
          "confidence": 0.9906054139137268
        },
        {
          "text": "provided that SFJ shall only be entitled to withhold such consent as to a Licensing Transaction other than an Excluded Licensing",
          "bbox": [
            274.0,
            928.0,
            2960.0,
            992.0
          ],
          "confidence": 0.9983089566230774
        },
        {
          "text": "Transaction in the event SFJ reasonably determines, and provides PB with written notice of its determination within [***] of PB",
          "bbox": [
            277.0,
            998.0,
            2954.0,
            1051.0
          ],
          "confidence": 0.9903832077980042
        },
        {
          "text": "providing to SFJ a non-binding term sheet or comparable document summarizing the material terms of the proposed Licensing",
          "bbox": [
            277.0,
            1069.0,
            2920.0,
            1120.0
          ],
          "confidence": 0.9918771386146545
        },
        {
          "text": "Transaction [***], that PB entering into such Licensing Transaction would [***] (\"Material Impact'). If PB disagrees with SFJ's",
          "bbox": [
            279.0,
            1133.0,
            2974.0,
            1182.0
          ],
          "confidence": 0.9785155057907104
        },
        {
          "text": "determination, the matter shall be submitted to arbitration before a single neutral arbitrator under the American Arbitration.",
          "bbox": [
            281.0,
            1204.0,
            2828.0,
            1248.0
          ],
          "confidence": 0.9865661263465881
        },
        {
          "text": "Association's (AAA's) expedited arbitration rules, which arbitrator shall be mutually agreeable to both Parties and have significant",
          "bbox": [
            283.0,
            1272.0,
            2991.0,
            1316.0
          ],
          "confidence": 0.9960454106330872
        },
        {
          "text": "expertise on the subject matter to be decided (provided that if the Parties have not mutually agreed on such arbitrator within J***]",
          "bbox": [
            279.0,
            1334.0,
            3003.0,
            1385.0
          ],
          "confidence": 0.9911063313484192
        },
        {
          "text": "arbitrator's award to be rendered within [***] of the applicable demand for arbitration. The sole issue to be decided in the",
          "bbox": [
            277.0,
            1464.0,
            2857.0,
            1520.0
          ],
          "confidence": 0.9937563538551331
        },
        {
          "text": "arbitration shall be whether the entry into such Licensing Transaction by PB would have a substantial likelihood of having a",
          "bbox": [
            281.0,
            1535.0,
            2842.0,
            1584.0
          ],
          "confidence": 0.9949465394020081
        },
        {
          "text": "Material Impact. In the event the arbitrator agrees with SFJ, PB shall not be entitled to enter into such Licensing Transaction. In the.",
          "bbox": [
            275.0,
            1599.0,
            3025.0,
            1650.0
          ],
          "confidence": 0.9912943243980408
        },
        {
          "text": "event the arbitrator agrees with PB, PB shall be entitled to enter into the Licensing Transaction; [***], and, [***].",
          "bbox": [
            276.0,
            1663.0,
            2663.0,
            1723.0
          ],
          "confidence": 0.987165093421936
        },
        {
          "text": "7.5.6 Sales of Royalty Streams. PB shall not sell, transfer or assign, directly or indirectly, in whole or in part, any",
          "bbox": [
            613.0,
            1785.0,
            2965.0,
            1844.0
          ],
          "confidence": 0.9877910614013672
        },
        {
          "text": "rights to receive payments of royalties or license fees with respect to the Product or the PB Intellectual Property (including any.",
          "bbox": [
            275.0,
            1858.0,
            2925.0,
            1915.0
          ],
          "confidence": 0.9946429133415222
        },
        {
          "text": "Accounts with respect to such royalties or license fees), other than to a wholly owned direct or indirect subsidiary of PB (it being",
          "bbox": [
            274.0,
            1919.0,
            2982.0,
            1986.0
          ],
          "confidence": 0.992828369140625
        },
        {
          "text": "understood that the foregoing shall not restrict the creation of any Permitted Lien).",
          "bbox": [
            281.0,
            1997.0,
            1992.0,
            2041.0
          ],
          "confidence": 0.9953686594963074
        },
        {
          "text": "7.5.7 Further Negative Pledges. PB shall not, from and after the Effective Date, enter into any agreement that",
          "bbox": [
            613.0,
            2114.0,
            2905.0,
            2167.0
          ],
          "confidence": 0.994815468788147
        },
        {
          "text": "prohibits or limits the ability of PB to create, incur, assume or suffer to exist any Lien upon any PB Intellectual Property (including",
          "bbox": [
            279.0,
            2187.0,
            2983.0,
            2239.0
          ],
          "confidence": 0.9867552518844604
        },
        {
          "text": "any Accounts with respect to such royalties or license fees), whether now owned or hereafter acquired, to secure the PB.",
          "bbox": [
            277.0,
            2251.0,
            2815.0,
            2304.0
          ],
          "confidence": 0.993133008480072
        },
        {
          "text": "Obligations, other than (a) agreements with SFJ (including this Agreement), (b) any agreements governing purchase money Liens",
          "bbox": [
            277.0,
            2319.0,
            2973.0,
            2372.0
          ],
          "confidence": 0.9937551021575928
        },
        {
          "text": "or capital lease obligations otherwise permitted hereby (in which case, any such prohibition or limitation shall only be effective on",
          "bbox": [
            281.0,
            2390.0,
            2969.0,
            2434.0
          ],
          "confidence": 0.998075544834137
        },
        {
          "text": "the assets financed thereby), (c) customary restrictions on assignment contained in leases, licenses or other",
          "bbox": [
            279.0,
            2454.0,
            2510.0,
            2503.0
          ],
          "confidence": 0.9929087162017822
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9840149283409119
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Any subcontractor, including any Permitted Third Party, who provides professional services to such Party for the Clinical Trials, will obtain Professional Liability Insurance in lieu of Clinical Trial Insurance, with a minimum limit of [***] dollars ($[***]) per occurrence.",
      "page_number": 4,
      "words": [
        {
          "text": "1.1.37 \"CMC\" means chemistry, manufacturing and controls.",
          "bbox": [
            616.0,
            336.0,
            1892.0,
            387.0
          ],
          "confidence": 0.9906229972839355
        },
        {
          "text": "1.1.38 \"CMC Information\" means the CMC information intended or required for the submission of an IND or",
          "bbox": [
            616.0,
            464.0,
            2929.0,
            510.0
          ],
          "confidence": 0.9926297664642334
        },
        {
          "text": "BLA.",
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ],
          "confidence": 0.9989228248596191
        },
        {
          "text": "1.1.39 \"CMO\" means contract manufacturing organization or contract development and manufacturing",
          "bbox": [
            614.0,
            654.0,
            2768.0,
            709.0
          ],
          "confidence": 0.9910363554954529
        },
        {
          "text": "organization.",
          "bbox": [
            277.0,
            723.0,
            540.0,
            781.0
          ],
          "confidence": 0.9975845813751221
        },
        {
          "text": "1.1.40 \"Commercial Launch' means, with respect to the Product and a country in the Territory, the first sale to a.",
          "bbox": [
            616.0,
            848.0,
            2971.0,
            899.0
          ],
          "confidence": 0.9816547632217407
        },
        {
          "text": "Third Party of such Product in such country after (a) Regulatory Approval and (b) in any country in which price approval is",
          "bbox": [
            281.0,
            925.0,
            2855.0,
            968.0
          ],
          "confidence": 0.984332263469696
        },
        {
          "text": "necessary or relevant for a majority of the population to obtain access to pharmaceutical products, price approval for such Product",
          "bbox": [
            275.0,
            987.0,
            3029.0,
            1038.0
          ],
          "confidence": 0.9829985499382019
        },
        {
          "text": "in such country.",
          "bbox": [
            277.0,
            1052.0,
            602.0,
            1106.0
          ],
          "confidence": 0.9959282875061035
        },
        {
          "text": "1.1.41 \"Commercialization'' or \"Commercialize\" means the commercial manufacture, marketing, promotion, sale",
          "bbox": [
            614.0,
            1175.0,
            2962.0,
            1228.0
          ],
          "confidence": 0.9898544549942017
        },
        {
          "text": "and/or distribution of the Product. For clarity, Commercialization excludes all activities associated with development and seeking",
          "bbox": [
            281.0,
            1246.0,
            2962.0,
            1294.0
          ],
          "confidence": 0.9963714480400085
        },
        {
          "text": "Regulatory Approval for the Product..",
          "bbox": [
            279.0,
            1312.0,
            1062.0,
            1363.0
          ],
          "confidence": 0.9807345271110535
        },
        {
          "text": "1.1.42 \"Commercially Reasonable Efforts\"' means with respect to the performance of activities under this",
          "bbox": [
            614.0,
            1436.0,
            2809.0,
            1486.0
          ],
          "confidence": 0.9854094982147217
        },
        {
          "text": "Agreement by a Party (as pertains to its role in conducting the Clinical Trials): reasonable, diligent, good-faith efforts to accomplish",
          "bbox": [
            277.0,
            1504.0,
            3011.0,
            1557.0
          ],
          "confidence": 0.9930388331413269
        },
        {
          "text": "such objective which are consistent with industry standards for companies of comparable size as that of such Party. \"Commercially",
          "bbox": [
            281.0,
            1577.0,
            3009.0,
            1621.0
          ],
          "confidence": 0.9955451488494873
        },
        {
          "text": "Reasonable Efforts' requires, with respect to a particular task or activity in making, using, selling, offering for sale, importing,",
          "bbox": [
            277.0,
            1639.0,
            2884.0,
            1692.0
          ],
          "confidence": 0.9913605451583862
        },
        {
          "text": "exporting, developing (including seeking regulatory approvals or applicable pricing or reimbursement approvals) or otherwise.",
          "bbox": [
            279.0,
            1705.0,
            2898.0,
            1758.0
          ],
          "confidence": 0.995408296585083
        },
        {
          "text": "commercializing the Product, that a Party: (i) promptly assign responsibility for such task or activity to specific employee(s) who.",
          "bbox": [
            279.0,
            1774.0,
            2953.0,
            1824.0
          ],
          "confidence": 0.9884916543960571
        },
        {
          "text": "are held accountable for progress and monitor such progress on an on-going basis; (ii) set and consistently seek to achieve specific",
          "bbox": [
            279.0,
            1840.0,
            3016.0,
            1889.0
          ],
          "confidence": 0.9896214604377747
        },
        {
          "text": "and meaningful objectives for carrying out such task or activity; and (iii) make and implement decisions and allocate resources.",
          "bbox": [
            281.0,
            1906.0,
            2911.0,
            1955.0
          ],
          "confidence": 0.994252622127533
        },
        {
          "text": "designed to advance progress with respect to such objectives in accordance with established timelines; provided, however, that, to",
          "bbox": [
            279.0,
            1972.0,
            3016.0,
            2023.0
          ],
          "confidence": 0.9976450800895691
        },
        {
          "text": "the extent that the performance of a Party's obligations hereunder is adversely affected by the other Party's breach in performing its",
          "bbox": [
            281.0,
            2043.0,
            3021.0,
            2087.0
          ],
          "confidence": 0.9909575581550598
        },
        {
          "text": "obligations hereunder, the impact on the first Party of such performance failure by the other Party will be taken into account in.",
          "bbox": [
            279.0,
            2105.0,
            2909.0,
            2156.0
          ],
          "confidence": 0.9834312796592712
        },
        {
          "text": "determining whether the first Party has used its Commercially Reasonable Efforts to perform any such affected obligations.",
          "bbox": [
            283.0,
            2176.0,
            2833.0,
            2220.0
          ],
          "confidence": 0.9969245195388794
        },
        {
          "text": "1.1.43 \"Competing Product\" means any agent intended to neutralize, abrogate or reverse the antiplatelet activity of",
          "bbox": [
            618.0,
            2299.0,
            3020.0,
            2343.0
          ],
          "confidence": 0.9894914627075195
        },
        {
          "text": "the Ticagrelor Compound.",
          "bbox": [
            279.0,
            2366.0,
            828.0,
            2416.0
          ],
          "confidence": 0.9743116497993469
        },
        {
          "text": "1.1.44 \"Completion Date\"' means, as to a particular Clinical Trial, the earlier of (a) the date of final database lock.",
          "bbox": [
            614.0,
            2489.0,
            2976.0,
            2538.0
          ],
          "confidence": 0.9890645742416382
        },
        {
          "text": "for such Clinical Trial and (b) the date such Clinical Trial or this Agreement is terminated.",
          "bbox": [
            281.0,
            2560.0,
            2132.0,
            2604.0
          ],
          "confidence": 0.9939261674880981
        },
        {
          "text": "1.1.45 \"Confidential Information\" of a Party means all information and materials provided and/or disclosed",
          "bbox": [
            618.0,
            2683.0,
            2847.0,
            2726.0
          ],
          "confidence": 0.9938953518867493
        },
        {
          "text": "(including in written form, electronic form or otherwise) by,",
          "bbox": [
            277.0,
            2748.0,
            1512.0,
            2805.0
          ],
          "confidence": 0.9992232918739319
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9815122485160828
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BLA.",
          "page": 4,
          "bbox": [
            274.0,
            530.0,
            401.0,
            583.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Any subcontractor, including any Permitted Third Party, who provides professional services to such Party for the Clinical Trials, will obtain Professional Liability Insurance in lieu of Clinical Trial Insurance, with a minimum limit of [***] dollars ($[***]) per occurrence.",
      "page_number": 5,
      "words": [
        {
          "text": "or on behalf of, such Party or its Affiliates, agents or representatives to the other Party, its Affiliates, agents or representatives in",
          "bbox": [
            279.0,
            344.0,
            2947.0,
            389.0
          ],
          "confidence": 0.9903295040130615
        },
        {
          "text": "connection with this Agreement, including, technical, scientific, regulatory and other information, results, knowledge, techniques,",
          "bbox": [
            277.0,
            407.0,
            2945.0,
            461.0
          ],
          "confidence": 0.9954399466514587
        },
        {
          "text": "data, analyses, inventions, invention disclosures, plans, processes, methods, know-how, ideas, concepts, test data (including",
          "bbox": [
            277.0,
            475.0,
            2878.0,
            528.0
          ],
          "confidence": 0.9937788248062134
        },
        {
          "text": "pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing.",
          "bbox": [
            277.0,
            543.0,
            2860.0,
            594.0
          ],
          "confidence": 0.9927600026130676
        },
        {
          "text": "pricing, distribution, cost, sales, and manufacturing data and descriptions. In addition, the terms and conditions of this Agreement",
          "bbox": [
            277.0,
            607.0,
            2976.0,
            660.0
          ],
          "confidence": 0.9966555237770081
        },
        {
          "text": "shall be deemed to be Confidential Information of both SFJ and PB. For further clarity, the terms of the AZ License shall be",
          "bbox": [
            277.0,
            672.0,
            2875.0,
            724.0
          ],
          "confidence": 0.9866896867752075
        },
        {
          "text": "considered the Confidential Information of PB, and SFJ acknowledges that the terms of the AZ License are also considered",
          "bbox": [
            281.0,
            744.0,
            2876.0,
            788.0
          ],
          "confidence": 0.9927793741226196
        },
        {
          "text": "\"Confidential Information' (as defined in the AZ License) of MedImmune, and that each of PB and MedImmune is deemed to be",
          "bbox": [
            279.0,
            804.0,
            2987.0,
            857.0
          ],
          "confidence": 0.9931616187095642
        },
        {
          "text": "the \"receiving Party\"' and the \"disclosing Party\"' with respect thereto for purposes of the AZ License. Notwithstanding the",
          "bbox": [
            279.0,
            875.0,
            2815.0,
            925.0
          ],
          "confidence": 0.9845126867294312
        },
        {
          "text": "foregoing, any AstraZeneca Product Know-How and any AstraZeneca Product Improvement shall be deemed to be the",
          "bbox": [
            277.0,
            941.0,
            2808.0,
            994.0
          ],
          "confidence": 0.9995084404945374
        },
        {
          "text": "Confidential Information of PB for purposes of this Agreement and of MedImmune for purposes of the AZ License, and SFJ shall",
          "bbox": [
            277.0,
            1009.0,
            3000.0,
            1058.0
          ],
          "confidence": 0.9910944700241089
        },
        {
          "text": "be deemed to be the receiving Party and PB shall be deemed to be the disclosing Party with respect thereto for purposes of this",
          "bbox": [
            279.0,
            1078.0,
            2956.0,
            1122.0
          ],
          "confidence": 0.9964855909347534
        },
        {
          "text": "Agreement (it being understood that MedImmune is deemed to be the \"receiving Party'' and MedImmune is deemed to be the",
          "bbox": [
            281.0,
            1142.0,
            2916.0,
            1191.0
          ],
          "confidence": 0.9885003566741943
        },
        {
          "text": "\"disclosing Party\"' with respect thereto for purposes of the AZ License). In addition, notwithstanding SFJ's ownership of the",
          "bbox": [
            275.0,
            1204.0,
            2876.0,
            1261.0
          ],
          "confidence": 0.9822927713394165
        },
        {
          "text": "Research Results prior to assignment thereof in accordance with Section 11.1.1.4, the Research Results shall at all times be",
          "bbox": [
            279.0,
            1275.0,
            2862.0,
            1325.0
          ],
          "confidence": 0.9935576915740967
        },
        {
          "text": "deemed to be Confidential Information of PB, and PB and SFJ shall be deemed the disclosing Party and the receiving Party,",
          "bbox": [
            277.0,
            1334.0,
            2880.0,
            1396.0
          ],
          "confidence": 0.9958563446998596
        },
        {
          "text": "respectively, with respect thereto.",
          "bbox": [
            275.0,
            1409.0,
            981.0,
            1460.0
          ],
          "confidence": 0.9998310804367065
        },
        {
          "text": "1.1.46 \"Contingent Liabilities\"' means, for any Person, (i) Indebtedness (as defined in Section 7.7.3) of that",
          "bbox": [
            614.0,
            1531.0,
            2856.0,
            1581.0
          ],
          "confidence": 0.9910394549369812
        },
        {
          "text": "Person, and (ii) any direct or indirect liability, contingent or not, of that Person for (a) warranty obligations, (b) potential claims for",
          "bbox": [
            279.0,
            1603.0,
            2994.0,
            1652.0
          ],
          "confidence": 0.9992796778678894
        },
        {
          "text": "damages, (c) assessments, and (d) any other condition, situation or set of circumstances involving various degrees of uncertainty",
          "bbox": [
            277.0,
            1668.0,
            2953.0,
            1720.0
          ],
          "confidence": 0.9966703653335571
        },
        {
          "text": "that may result in a loss or liability.",
          "bbox": [
            277.0,
            1732.0,
            988.0,
            1785.0
          ],
          "confidence": 0.983894944190979
        },
        {
          "text": "1.1.47 \"Control'' or \"Controlled' means (a) for Intellectual Property, a Party's ability to grant applicable licenses.",
          "bbox": [
            613.0,
            1855.0,
            2976.0,
            1908.0
          ],
          "confidence": 0.9868646860122681
        },
        {
          "text": "sublicenses and/or other rights thereunder and (b) for materials and documents, a Party's ability to provide, or provide access to,",
          "bbox": [
            277.0,
            1926.0,
            2980.0,
            1977.0
          ],
          "confidence": 0.9957748055458069
        },
        {
          "text": "such materials and/or documents, each without violating any contractual obligations to a Third Party. For clarity, if a Party only can",
          "bbox": [
            279.0,
            1995.0,
            3007.0,
            2045.0
          ],
          "confidence": 0.9897483587265015
        },
        {
          "text": "grant a license or sublicense and/or provide rights and/or access of limited scope, for a specific purpose or under certain conditions",
          "bbox": [
            279.0,
            2061.0,
            3025.0,
            2111.0
          ],
          "confidence": 0.9985711574554443
        },
        {
          "text": "due to an encumbrance, \"Control'' or \"Controlled' will be construed to so limit such license, sublicense, provision of rights and/or",
          "bbox": [
            277.0,
            2125.0,
            2987.0,
            2176.0
          ],
          "confidence": 0.9914212226867676
        },
        {
          "text": "access.",
          "bbox": [
            276.0,
            2202.0,
            430.0,
            2240.0
          ],
          "confidence": 0.8855510950088501
        },
        {
          "text": "1.1.48 \"Copyrights\" means, collectively, all works of authorship, mask works and any and all other registered and",
          "bbox": [
            614.0,
            2313.0,
            3000.0,
            2366.0
          ],
          "confidence": 0.9891541600227356
        },
        {
          "text": "unregistered copyrights and copyrightable works, and all applications, registrations, extensions, and renewals thereof.",
          "bbox": [
            279.0,
            2385.0,
            2735.0,
            2438.0
          ],
          "confidence": 0.9995512366294861
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9838435053825378
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Coverage must be maintained for as long as required by Applicable Law in each country after release of the last Subject from the Clinical Trials or where there is no legal requirement at least [***] after the termination of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Coverage must be maintained for as long as required by Applicable Law in each country after release of the last Subject from the Clinical Trials or where there is no legal requirement at least [***] after the termination of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Any deductibles for such insurance policies will be assumed by the insuring Party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_37",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Clinical Trials Liability: [***] dollars ($[***]) per occurrence.",
      "page_number": 37,
      "words": [
        {
          "text": "3.19 Exclusivity Commitment of SFJ. During the applicable Exclusive Period, SFJ shall not, and shall cause its Affiliates",
          "bbox": [
            446.0,
            342.0,
            2949.0,
            391.0
          ],
          "confidence": 0.9910616278648376
        },
        {
          "text": "not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold:",
          "bbox": [
            279.0,
            411.0,
            2637.0,
            459.0
          ],
          "confidence": 0.988855242729187
        },
        {
          "text": "3.19.1 any Competing Product (other than Product) alone or in combination (whether fixed dose or co-packaged)",
          "bbox": [
            613.0,
            534.0,
            3014.0,
            588.0
          ],
          "confidence": 0.9927142262458801
        },
        {
          "text": "with one (1) or more other active ingredients;",
          "bbox": [
            283.0,
            605.0,
            1227.0,
            654.0
          ],
          "confidence": 0.9981689453125
        },
        {
          "text": "3.19.2 any combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients of the",
          "bbox": [
            613.0,
            725.0,
            2992.0,
            777.0
          ],
          "confidence": 0.9919410347938538
        },
        {
          "text": "Product and a Competing Product;.",
          "bbox": [
            277.0,
            797.0,
            1017.0,
            850.0
          ],
          "confidence": 0.9673622250556946
        },
        {
          "text": "3.19.3 any agent that is intended as an antidote to, or is intended to neutralize, abrogate or reverse the antiplatelet",
          "bbox": [
            613.0,
            919.0,
            2992.0,
            970.0
          ],
          "confidence": 0.9871757626533508
        },
        {
          "text": "activity of, (i) any Brilinta Competing Product alone or in combination (whether fixed dose or co-packaged) with one (1) or more",
          "bbox": [
            283.0,
            994.0,
            2991.0,
            1038.0
          ],
          "confidence": 0.9983778595924377
        },
        {
          "text": "other active ingredients or (ii) both the Ticagrelor Compound and a Brilinta Competing Product;.",
          "bbox": [
            279.0,
            1056.0,
            2287.0,
            1109.0
          ],
          "confidence": 0.9923596978187561
        },
        {
          "text": "3.19.4 without limitation to the foregoing, any agent with dual activity as (i) an antidote to, or for use as an agent to",
          "bbox": [
            611.0,
            1177.0,
            3014.0,
            1233.0
          ],
          "confidence": 0.9911354184150696
        },
        {
          "text": "neutralize, abrogate or reverse the antiplatelet activity of, the Ticagrelor Compound and (ii) an antidote to, or for use as an agent to",
          "bbox": [
            279.0,
            1255.0,
            3016.0,
            1299.0
          ],
          "confidence": 0.9935830235481262
        },
        {
          "text": "neutralize, abrogate or reverse the antiplatelet activity of, any Brilinta Competing Product; or.",
          "bbox": [
            277.0,
            1316.0,
            2217.0,
            1369.0
          ],
          "confidence": 0.9846854209899902
        },
        {
          "text": "3.19.5 any Brilinta Competing Product..",
          "bbox": [
            616.0,
            1438.0,
            1437.0,
            1489.0
          ],
          "confidence": 0.9877067804336548
        },
        {
          "text": "3.20 Program Transfer. In the event that, at any time after payment to PB of the Initial Development Cost Payment on the.",
          "bbox": [
            448.0,
            1566.0,
            2991.0,
            1615.0
          ],
          "confidence": 0.9967399835586548
        },
        {
          "text": "Initial Funding Date, PB shall (a) fail to pay any amounts payable to SFJ hereunder within [***] of the date such payment is due,",
          "bbox": [
            275.0,
            1632.0,
            2976.0,
            1688.0
          ],
          "confidence": 0.9913357496261597
        },
        {
          "text": "or (b) become in default of its obligations under the AZ License (excluding (x) any such default that would not entitle AZ to",
          "bbox": [
            277.0,
            1699.0,
            2858.0,
            1756.0
          ],
          "confidence": 0.9996911287307739
        },
        {
          "text": "terminate the AZ License and (y) any such default that is caused by SFJ's breach of its obligations under this Agreement), or (c) (i).",
          "bbox": [
            277.0,
            1769.0,
            3016.0,
            1820.0
          ],
          "confidence": 0.991926372051239
        },
        {
          "text": "fail to remedy the Going Concern Condition within the Going Concern Cure Period as set forth in Section 3.18.3 or (ii) refuse to",
          "bbox": [
            279.0,
            1836.0,
            2971.0,
            1886.0
          ],
          "confidence": 0.9922879934310913
        },
        {
          "text": "accept the Going Concern Funding if offered by SFJ as set forth in Section 4.2.4, then, SFJ may deliver written notice to PB.",
          "bbox": [
            277.0,
            1900.0,
            2893.0,
            1953.0
          ],
          "confidence": 0.9941694140434265
        },
        {
          "text": "electing to cause PB's business related to the Product to be transferred to SFJ (the \"Program Transfer Notice'), and shall deliver a",
          "bbox": [
            281.0,
            1972.0,
            3018.0,
            2016.0
          ],
          "confidence": 0.9987497925758362
        },
        {
          "text": "copy of the Program Transfer Notice to MedImmune concurrently with delivery to PB, and within [***] following the delivery of",
          "bbox": [
            277.0,
            2034.0,
            2983.0,
            2087.0
          ],
          "confidence": 0.9921600222587585
        },
        {
          "text": "the Program Transfer Notice, PB and SFJ shall execute and deliver a Program Transfer Agreement in the form attached hereto as",
          "bbox": [
            281.0,
            2105.0,
            2992.0,
            2149.0
          ],
          "confidence": 0.9976071119308472
        },
        {
          "text": "Exhibit O (the \"Program Transfer Agreement') which shall effect the Program Transfer effective as of the date SFJ delivers the",
          "bbox": [
            279.0,
            2171.0,
            2927.0,
            2220.0
          ],
          "confidence": 0.9923612475395203
        },
        {
          "text": "Program Transfer Notice to PB. For clarity, this Section 3.20 shall not be effective prior to payment to PB of the Initial.",
          "bbox": [
            281.0,
            2238.0,
            2768.0,
            2282.0
          ],
          "confidence": 0.9863651394844055
        },
        {
          "text": "Development Cost Payment on the Initial Funding Date..",
          "bbox": [
            281.0,
            2306.0,
            1445.0,
            2350.0
          ],
          "confidence": 0.9826198220252991
        },
        {
          "text": "ARTICLE 4",
          "bbox": [
            1508.0,
            2425.0,
            1791.0,
            2469.0
          ],
          "confidence": 0.9569909572601318
        },
        {
          "text": "DEVELOPMENT COSTS",
          "bbox": [
            1345.0,
            2562.0,
            1961.0,
            2604.0
          ],
          "confidence": 0.9994592070579529
        },
        {
          "text": "4.1 Development Costs. SFJ will be obligated to pay or incur up to One Hundred Twenty Million U.S. Dollars",
          "bbox": [
            446.0,
            2741.0,
            2768.0,
            2790.0
          ],
          "confidence": 0.9903972744941711
        },
        {
          "text": "($120,o00,o00.00) of Development Costs (\"Maximum Development Costs') in accordance with the funding schedule set forth in.",
          "bbox": [
            281.0,
            2809.0,
            2992.0,
            2860.0
          ],
          "confidence": 0.9728729724884033
        },
        {
          "text": "Section 4.2. Any",
          "bbox": [
            277.0,
            2870.0,
            637.0,
            2931.0
          ],
          "confidence": 0.9968712329864502
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1541.0,
            4479.0
          ],
          "confidence": 0.9828983545303345
        }
      ],
      "nearby_headers": [
        {
          "text": "ARTICLE 4",
          "page": 37,
          "bbox": [
            1508.0,
            2425.0,
            1791.0,
            2469.0
          ]
        },
        {
          "text": "DEVELOPMENT COSTS",
          "page": 37,
          "bbox": [
            1345.0,
            2562.0,
            1961.0,
            2604.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_73",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Umbrella Excess Liability: [***] dollars ($[***]) per occurrence.",
      "page_number": 73,
      "words": [
        {
          "text": "12.3.2.2 Umbrella Excess Liability: [***] dollars ($[***]) per occurrence.",
          "bbox": [
            781.0,
            1308.0,
            2351.0,
            1372.0
          ],
          "confidence": 0.988617479801178
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commencing as of the Effective Date and thereafter during the Development Term, and subject to Section 12.3.2 below, each Party will carry and maintain, at its own expense, insurance coverage of the kind and with liability limits that, at a minimum, satisfy the requirements of Section 12.3.2, to protect itself and the other Party against any claims or liabilities that may arise from the conduct of the Clinical Trials and all other rights and obligations hereunder with insurers with a minimum \"A-\" A.M. Best rating.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Commencing as of the Effective Date and thereafter during the Development Term, and subject to Section 12.3.2 below, each Party will carry and maintain, at its own expense, insurance coverage of the kind and with liability limits that, at a minimum, satisfy the requirements of Section 12.3.2, to protect itself and the other Party against any claims or liabilities that may arise from the conduct of the Clinical Trials and all other rights and obligations hereunder with insurers with a minimum \"A-\" A.M. Best rating.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "PB will obtain such Clinical Trials Liability insurance on a global basis, and, if required, supplemented Clinical Trials Liability Insurance in the US, at its expense and SFJ will obtain supplemental Clinical Trials Liability insurance for the SFJ Territory and on a country specific basis in the European Clinical Trial Countries as required by Applicable Law at its expense, which will be considered Development Costs.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.21",
          "bbox": [
            2720.0,
            411.0,
            3025.0,
            459.0
          ],
          "confidence": 0.9994577169418335
        },
        {
          "text": "Certain information has been excluded from this agreement (indicated by \"[***]) because such information (i) is not material and (ii)",
          "bbox": [
            286.0,
            530.0,
            3018.0,
            579.0
          ],
          "confidence": 0.992963433265686
        },
        {
          "text": "would be competitively harmful if publicly disclosed.",
          "bbox": [
            1122.0,
            596.0,
            2182.0,
            640.0
          ],
          "confidence": 0.9946634769439697
        },
        {
          "text": "EXECUTION",
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ],
          "confidence": 0.9990861415863037
        },
        {
          "text": "VERSION",
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ],
          "confidence": 0.9976779818534851
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ],
          "confidence": 0.998929500579834
        },
        {
          "text": "This Co-Development Agreement (\"Agreement'), made effective as of January 9, 2020 (the \"Effective Date'), is by and.",
          "bbox": [
            446.0,
            981.0,
            2973.0,
            1032.0
          ],
          "confidence": 0.9742066860198975
        },
        {
          "text": "between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway,.",
          "bbox": [
            274.0,
            1043.0,
            2949.0,
            1106.0
          ],
          "confidence": 0.9890925884246826
        },
        {
          "text": "Suite 30, Malvern, Pennsylvania 19355, USA (\"PB'), and SFJ Pharmaceuticals X, Ltd. (\"SFJ\"), an SFJ Pharmaceuticals Group",
          "bbox": [
            277.0,
            1115.0,
            2978.0,
            1170.0
          ],
          "confidence": 0.9816502332687378
        },
        {
          "text": "company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at",
          "bbox": [
            281.0,
            1188.0,
            2942.0,
            1232.0
          ],
          "confidence": 0.9937464594841003
        },
        {
          "text": "SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a \"Party'' and collectively, the",
          "bbox": [
            281.0,
            1254.0,
            2998.0,
            1297.0
          ],
          "confidence": 0.9900888204574585
        },
        {
          "text": "\"Parties\").",
          "bbox": [
            279.0,
            1314.0,
            492.0,
            1369.0
          ],
          "confidence": 0.8950351476669312
        },
        {
          "text": "WHEREAS, SFJ is in the business of facilitating, among other things, the development and approval of pharmaceutical.",
          "bbox": [
            450.0,
            1440.0,
            2929.0,
            1489.0
          ],
          "confidence": 0.9960028529167175
        },
        {
          "text": "products and desires to provide financing and participate in conducting the Clinical Trials for the development of the Product as a.",
          "bbox": [
            277.0,
            1506.0,
            2983.0,
            1557.0
          ],
          "confidence": 0.9973935484886169
        },
        {
          "text": "treatment of patients for the reversal of the effects of the Ticagrelor Compound; and",
          "bbox": [
            275.0,
            1571.0,
            2034.0,
            1623.0
          ],
          "confidence": 0.9909263849258423
        },
        {
          "text": "WHEREAS, PB has rights to the Product, is conducting clinical trials of the Product in the United States and the European",
          "bbox": [
            448.0,
            1696.0,
            3018.0,
            1745.0
          ],
          "confidence": 0.9945514798164368
        },
        {
          "text": "Clinical Trial Countries, and would like to enter into an agreement with SFJ to provide operational support for the conduct of",
          "bbox": [
            277.0,
            1760.0,
            2904.0,
            1811.0
          ],
          "confidence": 0.9970331192016602
        },
        {
          "text": "clinical trials of the Product in the European Clinical Trial Countries, to conduct clinical trials of the Product in the Designated Asian.",
          "bbox": [
            279.0,
            1827.0,
            3021.0,
            1879.0
          ],
          "confidence": 0.9948242902755737
        },
        {
          "text": "Countries, and to provide global financing for the continued development of the Product..",
          "bbox": [
            281.0,
            1899.0,
            2132.0,
            1942.0
          ],
          "confidence": 0.9912284016609192
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable.",
          "bbox": [
            440.0,
            2014.0,
            2771.0,
            2070.0
          ],
          "confidence": 0.9883178472518921
        },
        {
          "text": "consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            285.0,
            2089.0,
            2211.0,
            2133.0
          ],
          "confidence": 0.9866514205932617
        },
        {
          "text": "ARTICLE 1 ",
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ],
          "confidence": 0.9371867179870605
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ],
          "confidence": 0.9976634383201599
        },
        {
          "text": "1.1 Defined Terms. Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the.",
          "bbox": [
            446.0,
            2461.0,
            2985.0,
            2513.0
          ],
          "confidence": 0.9913411736488342
        },
        {
          "text": "following terms which will have the following respective meanings:",
          "bbox": [
            279.0,
            2533.0,
            1653.0,
            2586.0
          ],
          "confidence": 0.985741913318634
        },
        {
          "text": "1.1.1 \"Account' is any \"account' as defined in the UCC with such additions as such term may hereafter be made",
          "bbox": [
            613.0,
            2653.0,
            2985.0,
            2704.0
          ],
          "confidence": 0.9910066723823547
        },
        {
          "text": "and includes, without limitation, all accounts receivable and other sums owing to PB.",
          "bbox": [
            285.0,
            2730.0,
            2035.0,
            2774.0
          ],
          "confidence": 0.9920226335525513
        },
        {
          "text": "1.1.2 \"Affiliate\"' means, with respect to a party, a business entity under common control with, or controlling or.",
          "bbox": [
            611.0,
            2845.0,
            2915.0,
            2904.0
          ],
          "confidence": 0.9862533211708069
        },
        {
          "text": "controlled by, such party, with \"control' meaning direct or indirect ownership of 50% or more of the voting interest in such other.",
          "bbox": [
            277.0,
            2918.0,
            2963.0,
            2969.0
          ],
          "confidence": 0.9923608303070068
        },
        {
          "text": "entity, and in the case",
          "bbox": [
            279.0,
            2984.0,
            727.0,
            3037.0
          ],
          "confidence": 0.9858542084693909
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            332.0,
            4437.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9867796897888184
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "EXECUTION",
          "page": 0,
          "bbox": [
            2719.0,
            731.0,
            3025.0,
            769.0
          ]
        },
        {
          "text": "VERSION",
          "page": 0,
          "bbox": [
            2786.0,
            793.0,
            3029.0,
            842.0
          ]
        },
        {
          "text": "CO-DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1205.0,
            892.0,
            2099.0,
            928.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1515.0,
            2211.0,
            1794.0,
            2249.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1474.0,
            2343.0,
            1831.0,
            2381.0
          ]
        }
      ]
    },
    {
      "id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "PB will obtain such Clinical Trials Liability insurance on a global basis, and, if required, supplemented Clinical Trials Liability Insurance in the US, at its expense and SFJ will obtain supplemental Clinical Trials Liability insurance for the SFJ Territory and on a country specific basis in the European Clinical Trial Countries as required by Applicable Law at its expense, which will be considered Development Costs.",
      "page_number": 1,
      "words": [
        {
          "text": "of a partnership, control of the general partner. Notwithstanding the foregoing, neither The Blackstone Group Inc. nor any of its",
          "bbox": [
            283.0,
            342.0,
            2940.0,
            386.0
          ],
          "confidence": 0.9971181154251099
        },
        {
          "text": "divisions, including Blackstone Life Sciences, shall be deemed to be an \"Affiliate\" of SFJ.",
          "bbox": [
            279.0,
            402.0,
            2148.0,
            453.0
          ],
          "confidence": 0.9810135364532471
        },
        {
          "text": "1.1.3 \"Alliance Manager' has the meaning ascribed to such term in Section 5.1.5.",
          "bbox": [
            618.0,
            526.0,
            2320.0,
            576.0
          ],
          "confidence": 0.9932347536087036
        },
        {
          "text": "1.1.4 \"Anti-Corruption Laws\"' means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act",
          "bbox": [
            613.0,
            651.0,
            2973.0,
            705.0
          ],
          "confidence": 0.9872748255729675
        },
        {
          "text": "2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money",
          "bbox": [
            279.0,
            722.0,
            2869.0,
            777.0
          ],
          "confidence": 0.9936056137084961
        },
        {
          "text": "laundering or terrorism.",
          "bbox": [
            281.0,
            795.0,
            767.0,
            839.0
          ],
          "confidence": 0.9967710375785828
        },
        {
          "text": "1.1.5 \"Applicable Law' means the applicable laws, rules and regulations, including any rules, regulations,",
          "bbox": [
            613.0,
            910.0,
            2802.0,
            965.0
          ],
          "confidence": 0.9870105981826782
        },
        {
          "text": "guidelines, or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally.",
          "bbox": [
            281.0,
            985.0,
            2886.0,
            1034.0
          ],
          "confidence": 0.9907440543174744
        },
        {
          "text": "binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory. For clarity, Applicable",
          "bbox": [
            281.0,
            1054.0,
            2907.0,
            1098.0
          ],
          "confidence": 0.9904028177261353
        },
        {
          "text": "Laws will include the FFDCA, the PHSA, the Anti-Corruption Laws, and all laws, regulations and legally binding guidelines",
          "bbox": [
            277.0,
            1118.0,
            2869.0,
            1168.0
          ],
          "confidence": 0.9952269196510315
        },
        {
          "text": "applicable to the Clinical Trials, including GCP, GLP, GMP and ICH guidelines.",
          "bbox": [
            281.0,
            1184.0,
            1939.0,
            1235.0
          ],
          "confidence": 0.9940752983093262
        },
        {
          "text": "1.1.6 \"Approval Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.1.",
          "bbox": [
            620.0,
            1308.0,
            2547.0,
            1352.0
          ],
          "confidence": 0.9902095794677734
        },
        {
          "text": "1.1.7 \"Approval Payments\" has the meaning ascribed to such term in Section 6.1.",
          "bbox": [
            616.0,
            1433.0,
            2327.0,
            1482.0
          ],
          "confidence": 0.9969279766082764
        },
        {
          "text": "1.1.8 \"Approved CRO\" has the meaning ascribed to such term in Section 2.4.1.",
          "bbox": [
            616.0,
            1557.0,
            2300.0,
            1606.0
          ],
          "confidence": 0.9934296607971191
        },
        {
          "text": "1.1.9 \"Approved Third Party Vendor Costs\"' has the meaning ascribed to such term in Section 5.2.2.2(g).",
          "bbox": [
            614.0,
            1677.0,
            2824.0,
            1738.0
          ],
          "confidence": 0.985320508480072
        },
        {
          "text": "1.1.10 \"Approved Vendor' has the meaning ascribed to such term in Section 2.4.2..",
          "bbox": [
            614.0,
            1805.0,
            2365.0,
            1862.0
          ],
          "confidence": 0.9861373901367188
        },
        {
          "text": "1.1.11 \"AstraZeneca Product' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            1937.0,
            2465.0,
            1986.0
          ],
          "confidence": 0.992119550704956
        },
        {
          "text": "1.1.12 \"AstraZeneca Product Improvements'' has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2063.0,
            2786.0,
            2112.0
          ],
          "confidence": 0.9900959134101868
        },
        {
          "text": "1.1.13 \"AstraZeneca Product Know-How\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            613.0,
            2185.0,
            2744.0,
            2242.0
          ],
          "confidence": 0.9757313132286072
        },
        {
          "text": "1.1.14 \"AstraZeneca Product Patents\" has the meaning ascribed to such term in the AZ License.",
          "bbox": [
            616.0,
            2313.0,
            2641.0,
            2365.0
          ],
          "confidence": 0.9911542534828186
        },
        {
          "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
          "bbox": [
            330.0,
            4435.0,
            1542.0,
            4479.0
          ],
          "confidence": 0.9963463544845581
        }
      ],
      "multi_page": true,
      "part_of": 2
    }
  ]
}